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Chronic Smoke-Induced Functional and Morphological Ocular Injury. (Under the 
direction of BÄRBEL ROHRER).
BACKGROUND: Age-related macular degeneration (AMD), a complex disease 
involving genetic variants and environmental insults, is among the leading 
causes of blindness in Western populations. Genetic and histologic evidence 
implicate the complement system in AMD pathogenesis, and smoking is the 
major environmental risk factor associated with increased disease risk. Although 
previous studies have demonstrated that cigarette smoke exposure (CE) causes 
retinal pigment epithelium (RPE) defects in mice and smoking leads to 
complement activation in patients, it is unknown whether complement activation 
is causative in the development of CE pathology; and if so, which complement 
pathway is required.
METHODS: Mice were exposed to cigarette smoke or clean, filtered air for 6 
months. The effects of CE were analyzed in wildtype (WT) mice or mice without a 
functional complement alternative pathway (AP; CFB−/−) using molecular, 
histological, electrophysiological, and behavioral outcomes. A modified AP 
inhibitor, CR2-FH, was administered to WT mice for 3 months following CE to 
determine the effects of anti-complement-based-therapy on smoke-induced 
ocular pathology.
RESULTS: CE in WT mice exhibited a significant reduction in function of rods 
and cones as determined by electroretinography and contrast sensitivity 
xii
measurements, concomitant with a thinning of nuclear layers as measured by 
SD-OCT imaging and histology. Gene expression analyses suggested that 
alterations in photoreceptors and RPE/choroid may contribute to the observed 
loss of function, and visualization of complement C3d deposition implies the 
RPE/Bruch's membrane (BrM) complex as the target of AP activity. RPE/BrM 
alterations include an increase in mitochondrial size concomitant with an apical 
shift in mitochondrial distribution within the RPE and a thickening of BrM. CFB−/− 
mice were protected from developing CE-mediated alterations, and treatment 
with CR2-FH reversed existing damage in WT mice.
CONCLUSIONS: Taken together, these findings provide clear evidence that 
ocular pathology generated in CE mice is dependent on complement activation 
and requires the AP. Identifying animal models with RPE/BrM damage and 
verifying which aspects of pathology are dependent upon complement activation 
is essential for developing novel complement-based treatment approaches for 
the treatment of AMD.
xiii
CHAPTER 1
INTRODUCTION AND SPECIFIC AIMS
1
Introduction
 The first manifestations of senile macular degeneration were described in 
medical literature by the British ophthalmologist, Waren Tay, as “symmetrical 
central choroidoretinal disease occurring in senile persons.” This was renamed to 
its current alias, age-related macular degeneration (AMD), in the 1980s. AMD is 
a chronic, progressive eye disease that results in loss of central vision and is the 
leading cause of severe vision loss and blindness in Western populations. Vision 
loss occurs due to degeneration of the macula, the portion of the retina 
responsible for sharp, central vision. There are two major forms of AMD: atrophic 
(dry) and exudative (wet). 85-90% of AMD cases are atrophic, while only 10-15% 
represent the exudative form. Dry AMD is characterized by the formation of 
small, yellow deposits beneath the retina, called drusen, that are made up of 
metabolic end products generated by the retinal pigment epithelium (RPE). 
Patients experience a slow, progressive loss of vision which may start as blurred 
or distorted spots in the visual field. Over time, large areas of retinal thinning 
called geographic atrophy (GA) can develop causing severe vision loss. Wet 
AMD is characterized by a rapid loss of vision caused by abnormal blood vessel 
growth through Bruch’s membrane (BrM)  which then leak blood and proteins into 
the subretinal space. Over time, scar tissue can form near areas of 
neovascularization that can lead to the formation of subretinal abrasions known 
as disciform scars. Current estimates show that as many as 11 million people in 
the United States over the age of 50 have some form of AMD, and this number is 
expected to double by 2020. There is a substantial global burden of AMD with 
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projections of 196 million by 2020 and 288 million by 2040 [1]. The annual cost of 
AMD is estimated to be approximately $30 billion [2]. Data pooled from three 
population-based studies, the Beaver Dam Eye Study, the Rotterdam Study, and 
the Blue Mountain Eye Study, estimated the prevalence rate for AMD is about 
0.2% for individuals between 55-64 years, sharply increasing to 13% in those 
over the age of 85 [3].
Pathology of AMD
 The progression of AMD occurs over an extended period of time, with the 
incidence of disease increasing dramatically over the age of 70 [4]. AMD is a 
multifactorial disease that primarily affects the RPE, overlying photoreceptors, 
BrM, and choriocapillaris (CC). The main pathological features associated with 
AMD vary with the stage of disease. Here, we focus on the primary features of 
early/advanced stage, dry AMD (drusen formation and GA) and late stage,  wet 
AMD (subretinal neovascularization and disciform scar formation). 
 The hallmark indicators of early stage, dry AMD are pigmentary changes 
in the macula and the formation of drusen. In 1855, drusen were first described 
by Franciscus Donders, a Dutch ophthalmologist and one of the primary founders  
of scientific opthalmology [5]. He initially referred to them as “colloidkugeln” or 
colloid spheres. The German anatomist, Heinrich Müller, later gave them their 
name, derived from the German word for geodes, cavities in rocks often lined by 
crystals, based on their glittering appearance [6]. Drusen appear as small, 
yellow-white spots in the retina and are most often found as clusters within the 
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macular region. They are composed of complement proteins, inflammatory 
molecules, lipids, lipoproteins B and E, and glycoproteins [7] and are located 
between the basement membrane of the RPE and the inner collagenous layer 
(ICL) of BrM. Due to their position between the RPE and CC, it is possible that 
drusen impede the transfer of oxygen and nutrients from the vascular blood 
supply to the RPE and overlying photoreceptor cells. Likewise, they may also 
interfere with waste products being removed from the RPE. Clinically, drusen are 
classified morphologically as hard or soft. Hard drusen are small (<63 µm), 
round, isolated from one another, and have sharp borders. These are more 
common with age, but are mostly benign and not commonly associated with 
vision problems. In contrast, soft drusen are large (≥63 µm), variable in shape, 
have less defined borders, and tend to cluster close together. These are thought 
to be more harmful and are associated with a greater risk for developing AMD, 
including choroidal neovascularization (CNV) and GA [8]. 
 Drusen are associated with outer retina thinning in early/intermediate AMD 
[9]. Specifically, the photoreceptor outer nuclear layer (ONL) is thinner in areas 
overlying drusen, and corresponding photoreceptor inner and outer segment 
(OS) length is also reduced [10]. Furthermore, there is a strong correlation 
between retinal thinning and drusen height [9], rather than width. Retinal thinning 
in the photoreceptor layer suggests a degenerative process, with cell loss leading 
to decreased visual function. This hypothesis is supported by optical coherence 
tomography (OCT) imaging of hyperreflective foci that are visible above drusen in 
4
the ONL, likely representing photoreceptor degeneration and/or glial scar 
formation 
 A phenotypically distinct type of drusen, called called reticular 
pseudodrusen (RPD), were first described in 1990 as “les pseudodrusen bleus” 
due to their enhanced visibility under blue light [11]. RPD are subretinal deposits 
which appear as yellowish interlacing macular networks in the fundus. RPD 
accumulate above the RPE, between the apical membrane of the RPE and the 
IS/OS boundary. RPD are associated with an increased risk for progressing to 
both neovascular AMD and GA [12].
 In addition to drusen, accumulation of other deposit types is associated 
with AMD. Basal laminar deposits (BLamD) and basal linear deposits (BLinD) are 
subretinal deposits primarily comprised of phospholipids. BLamDs are found 
between the plasma and basement membranes of the RPE, while BLinDs are 
located external to the RPE basement membrane in the ICL of BrM. BLamDs 
may progress to BLinDs, which are associated with soft drusen and RPE 
detachments [13]. BLinDs are good markers for progression to late stage AMD, 
while the amount of BLamDs is associated with the degree of RPE atrophy and 
photoreceptor degeneration [14-16].
 The primary clinical characteristic of advanced stage, dry AMD is the 
appearance of retinal thinning, also known as GA. This is visualized as sharply 
delineated round or oval areas of hypopigmentation (>175 µm), signifying the 
absence of RPE, in which choroidal vessels are more visible than surrounding 
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areas [17]. According to the Age-Related Eye Disease Study (AREDS), the most 
common sequence of events leading to GA is the progression of a large drusen 
to hyperpigmentation, followed by regression of the drusen, hypopigmentation, 
and finally RPE cell death. Studies suggest that RPE cells are the primary target 
in GA and its death results in CC atrophy [18, 19]. In most cases, GA starts near 
the center of the macula and progresses outward to the periphery, forming 
islands of lost photoreceptor cells. The average enlargement rate of atrophic 
area is about 2.6 mm2/year and eyes with larger baseline atrophy have even 
higher enlargement rates [20]. As these areas of atrophy grow, blind spots, called 
scotomas, form in patients’ visual field caused by photoreceptor cell death. The 
decrease in number of rods, reduction in foveal cone function, and shift from 
central to eccentric fixation all contribute to a decrease in contrast sensitivity, 
reading rate, and dark adaptation in GA [21-23]. Decreases in rod-mediated dark 
adaptation are also consistent with normal aging and AMD, independent of GA 
[24].
 CNV is the defining feature of late stage, wet AMD. Neovascularization 
has two distinct etiologic patterns. The first and most common description of CNV 
is the growth of new vessels from the CC through BrM into the subretinal space 
[25]. The second, involves the development of vessels derived from retinal 
circulation in a process called retinal angiomatous proliferations (RAP), also 
known as deep retinal vascular anamalous complex or retinochoroidal 
anastomosis [26, 27]. These vessels extend outward from the neurosensory 
retina into the subretinal space, sometimes anastomosing with choroid-derived 
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vessels [28]. However, RAP occurs much less frequently than classical choroid-
derived neovascularization. Central vision loss can occur rapidly once CNV 
begins, and hemorrhaging of new blood vessels can accelerate the onset of 
vision loss. Ultimately, photoreceptors die from lack of nutrients, leakage of 
serum components from CNV, and scar formation [29]. Blood leakage and serous 
exudate resulting from CNV can also cause pigment epithelial detachment, a 
process in which the RPE separates from the underlying BrM [30]. 
 Left untreated, the natural course of late stage, wet AMD advances further 
to develop fibrous disciform scars, a result of subretinal neovascularization. 
Fibrous tissue can develop within BrM or between the RPE and retina resulting in 
a fibrotic scar (4-8 mm) underlying the macula. This is often accompanied by a 
central scotoma and causes severe vision loss. Hemoserdin is typically present 
in the lesions, suggesting hemorrhaging, a consequence of CNV, occurs prior to 
scar formation. Disciform scars cause the overlying retina to undergo cystic 
degeneration with photoreceptor loss. Blindness from neovascular wet AMD is 
associated with macular disciform scar formation and 360° peripapillary 
subretinal fibrosis, which may cause ischemic optic neuropathy [31]. Disciform 
scars may contribute to vision loss by creating an expanding band of RPE 
atrophy, possibly due to remodeling of choroidal circulation [32]. Interestingly, 
patients with bilateral disciform scars reported visual improvement in the first 
affected eye after development of scarring in both eyes [33].
 A growing body of literature suggests that dysfunctional mitochondria may 
lie at the core of AMD etiology [34, 35]. Feher et al. [36] have reported age-
7
related changes in mitochondrial morphology as analyzed in histological 
sections, that are accentuated in AMD. Aged RPE contain mitochondria that 
show membrane disorganization, a focal loss of cristae, and disruption of their 
apical-basal alignment. Work by He and Tombran-Tink [37] showed that cultured 
RPE cells from aged donor eyes contain large, fused mitochondria that generate 
less ATP than those obtained from young donors. RPE with reduced levels of 
ATP, a model of aged RPE in vitro, show reduced autophagy, OS phagocytic 
capacity, and increased oxidative load [38]. These studies suggest that 
dysfunctional mitochondria may impair the ability of the RPE to maintain it’s role 
in homeostasis due to an ATP deficiency.
 The vascular model of AMD proposed by Friedman and coworkers 
suggests that changes in the choroidal vasculature, similar to those observed in 
atherosclerosis, are responsible for the development of AMD [39]. Chronic smoke 
exposure has been shown to change clot dynamics and alter fibrin structure, both 
of which contribute to thrombosis [40]. Thromboregulatory functions might be 
further disrupted by a smoke-induced decrease in NTPDase, a plasma-
membrane-bound enzyme that breaks down precursor nucleotides into the 
antithrombotic and anti-inflammatory mediator, adenosine [41]. Smoke also 
induces vasoconstriction by activating alpha-adrenergic receptors. Collectively, 
these findings result in a decrease in choroidal blood flow. Friedman and 
colleagues proposed that this decrease in choroidal blood flow may impair the 
clearance of debris from the RPE and lead to the formation of deposits in BrM 
[42]. A decrease in blood flow might also be responsible for heat-related damage 
8
in the RPE/choroid, since light absorption by melanosomes results in an increase 
in temperature above 37° C [43]. Cigarette smoke might be responsible for 
inducing changes in angiogenesis. Smoke exposure can change the branching 
pattern in proliferating vessels of chick chorioallantoic membrane [44], 
concomitant with an increase in the number of fibroblasts and altered 
composition of the extracellular matrix present in these membranes affecting their 
structural integrity.
Risk Factors Associated with AMD
 AMD is a complex disease with multiple demographic, environmental, and 
genetic risk factors. Among the demographic and environmental risk factors 
associated with AMD, such as age, gender, race, exposure to sunlight, diet, 
smoking, education, and cardiovascular disease, studies have shown that the 
most consistent are increasing age and cigarette smoking [45]. Numerous genes 
have also been implicated as possible risk factors for AMD, with the strongest 
association between genes involved in immune modulation and the complement 
system [46-50]. Genetic predisposition to AMD may increase susceptibility to 
demographic and environmental risk factors as well.
Aging
 Age is the strongest risk factor associated with AMD. All population-based 
studies indicate that the prevalence of AMD increases with age in caucasians 
[14, 17, 51, 52]. According to the Blue Mountains Eye Study, the 5-year incidence 
rate of AMD increased from 3.2% (≤60 years) to 7.4% (60-69 years) to 18.3% 
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(70-79 years) in a population with no previous history of the disease [53]. These 
findings parallel those of the Beaver Dam Eye Study, which found that AMD risk 
increases more than three-fold in patients older than 75 years of age compared 
to those between 65-74 years [54]. The age-associated increase in AMD risk 
may be caused by gradual, cumulative damage to the retina as a result of 
chronic oxidative stress over a long period of time. The RPE acts as a 
specialized epithelial cell layer that provides metabolic support to overlying 
photoreceptor cells. Loss of physiological function due to oxidative stress may 
impair their ability to support photoreceptors, resulting in degeneration of these 
specialized, light-sensitive cells. Alternatively, age-related mitochondrial DNA 
damage may also play a role in pathogenesis.
Cigarette Smoke and Oxidative Stress
 Cigarette smoke is the only proven, modifiable risk factor associated with 
AMD. Previous studies found a two- to four-fold increased risk for developing 
AMD in smokers compared to nonsmokers [55]. Furthermore, smoking promotes 
the progression of AMD from the atrophic to neovascular form [56]. In addition to 
these epidemiological studies, some genetic studies have identified gene-
environment interactions between genetic risk factors and smoking in AMD. For 
example, Chakravarthy and colleagues confirmed a gene-environment 
interaction between age-related maculopathy susceptibility 2 (ARMS2) and 
cigarette smoke [57]; interactions between complement factor H and smoking 
have been found in some populations [58], but not others [59]; and variations in 
two single-nucleotide polymorphisms of apolipoprotein E were positively or 
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negatively associated with smoking in a genotype-specific manner [60]. Despite 
the links between smoking and AMD, little is known of the underlying cellular 
mechanisms by which cigarette smoke contributes to the pathology of AMD. 
There are several major mechanistic theories in the literature that contribute to 
AMD pathogenesis including oxidative stress, antioxidant depletion, complement 
activation and vascular changes.
 Oxidative stress, in reference to the cellular damage caused by an inability 
of biological systems to detoxify reactive oxygen species (ROS), has been 
implicated in a number of disease processes. ROS include superoxide, hydrogen 
peroxide, hydroxyl radicals, and other byproducts of oxygen metabolism. These 
ROS can damage all components of the cell, including proteins, lipids, and DNA, 
as well as disrupt cellular signaling pathways.
 Previous studies have shown that oxidative stress, involving the RPE in 
particular, is a major contributing factor in the etiology of AMD [61]. The RPE 
layer is exposed to potentially high levels of photo-oxidative stress from 
photoreceptor turnover and high levels of oxygen from the systemic circulation, 
which is, however, minimized due to the presence of endogenous antioxidants. If 
the detoxification system is compromised, oxidants and stimulators of cellular 
oxidative metabolism can then induce damage, potentially leading to apoptosis 
[62]. Without support from RPE cells, overlying photoreceptors will eventually 
undergo apoptosis, leading to permanent vision loss. This oxidative stress 
hypothesis is supported by the AREDS, which shows that nutritional 
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supplementation with antioxidants and zinc reduces the risk of early AMD 
patients progressing to advanced stages of AMD by approximately 25% [63].
 With each inhalation, cigarette smoke introduces a large number of free 
radicals [64] and likely contributes to oxidative damage loads. Oxidants found in 
cigarette smoke can pass through the alveolar walls and enter the systemic 
circulation, exerting widespread effects as evidenced by an increase in plasma 
markers of lipid peroxidation after smoking [65]. Oxidative damage can manifest 
itself in a variety of ways, including degradation of intracellular organelles, 
disruption of cell signaling pathways, and alterations in mitochondrial DNA. 
Fujihara and coworkers have shown that mice exposed to chronic cigarette 
smoke display signs of oxidative damage concomitant with ultrastructural 
changes including RPE damage and apoptosis, and thickening of BrM [66]. In 
addition to generating short-lived ROS, cigarette smoke contains a number of 
stable compounds which are also capable of generating oxidative damage. Most 
notable of these are acrolein, an unsaturated aldehyde capable of inducing 
protein modifications and enhancing the formation of advanced glycation end 
products and advanced lipid end products [67]; cadmium, a metal associated 
with zinc production that accumulates in the RPE and choroid, where it generates  
ROS [68]; and hydroquinone, a pro-oxidant compound, which itself can be 
oxidized and conjugated with glutathione to form potent mitochondrial toxins or 
cause DNA damage by covalently binding with DNA and inducing DNA oxidation 
via redoxcycling [69]. All three compounds have been shown to be associated 
with RPE cell damage using either in vitro or in vivo models [68, 70, 71].
12
 Aerobic organisms have integrated antioxidant systems to protect against 
oxidant-mediated cell damage. However, under pathological conditions these 
safeguards can easily become overwhelmed. Diet-derived vitamins B, C, and E 
provide protection by reacting with free radicals and preventing their propagation 
in tissues. However, plasma levels of vitamin C and carotenes are significantly 
lower in cigarette smokers when compared to nonsmokers [72], presumably as a 
consequence of enhanced turnover due to smoke-induced oxidative stress. 
Panda and colleagues supported this line of evidence by inhibiting smoke-
induced oxidative damage in vivo with vitamin C supplementation [73]. Smoke 
exposure also reduces the amount of endogenous circulating antioxidants; more 
specifically, glutathione and cysteine were both downregulated in smokers 
compared to nonsmokers [74]. Lastly, enzymes that degrade ROS and produce 
endogenous antioxidants such as superoxide dismutase (SOD) are also 
imperative in cellular defense against oxidative damage. SOD levels have been 
shown to be decreased in tissues of smokers [75], and eliminating SOD2 in mice 
results in “retinal damage similar to that associated with the early stages of age-
related macular degeneration” [76].
Inflammation
 It has long been recognized that inflammation plays a role in AMD, despite 
the fact that it does not present itself with the classical signs of inflammation such 
as heat and swelling. However, inflammatory processes, possibly being triggered 
by local cell damage or the accumulation of debris at the level of BrM, as well as 
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the invasion of inflammatory cells, have been documented in eyes of AMD 
patients. These local inflammatory alterations might then be propagated by the 
immune system, the choroidal vascular network, and other local cells. 
 The complement cascade is an integral part of the innate and adaptive 
immune system. Its main function is to help clear pathogens or nonself cells from 
the organism by either marking them for clearance by phagocytosis or by direct 
lysis. Several complement components have been found in drusen, BrM, and 
CNV membranes, and severity of AMD is correlated with the amount of 
complement membrane attack complex present at the level of the RPE/BrM [77]. 
Given the destructive potential of this system, a large number of complement 
inhibitors are expressed by the host or self-cells. However, the majority of these 
membrane-bound inhibitors are misregulated in AMD [78, 79].
 The inflammatory hypothesis gained further support when several genetic 
risk factors associated with AMD were identified as polymorphisms in 
complement genes such as complement inhibitor, complement factor H (CFH), 
complement factor B (CFB), and complement component 3 (C3) [80], and when 
some of these gene alterations were found to be associated with the progression 
of atrophic to neovascular AMD. Hence, complement therapeutics are currently 
being explored for the treatment of AMD [81].
 Cigarette smoke has been shown to directly activate the complement 
cascade via modification of C3 and subsequently activate the alternative pathway 
(AP) of complement [82]. Circulating CFH, the inhibitor of the AP, is also reduced 
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in smokers. While it has yet to be proven that smoking increases the risk for AMD 
by increasing complement activation, it is plausible that the combination of 
complement-related genetic risk factors and smoke-induced activation of the 
complement cascade may act synergistically to promote inflammation in 
AMD. 
Genetic Susceptibility
 A large body of literature suggests that there are numerous genetic risk 
factors involved in AMD [83, 84]. Several population-based studies implicate a 
familial component in the pathogenesis of AMD [85-87], including monozygotic 
and dizygotic twin studies. Klaver and colleagues estimated that siblings of 
individuals with late stage AMD have a five-fold increased risk for developing 
intermediate AMD and a twenty-fold increased risk for developing advanced AMD 
[86]. Furthermore, an attributable risk study conducted by Seddon and 
colleagues revealed that 80% of incident AMD is attributable to genetic factors 
[88].
 Many of the genes implicated in AMD risk involve a single nucleotide 
polymorphism (SNP) in which one amino acid within the protein is substituted for 
another. SNPs are typically a result of missense mutations, a point mutation in 
which a single nucleotide change results in a codon for a different amino acid. 
SNPs can have variable outcomes depending on the amino acid that is 
substituted. Mutations that give rise to substitution of similar amino acids (i.e. 
valine for alanine) may not modify the protein at all. However, substitution of 
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amino acids with different reactivity or charge (i.e. tyrosine for leucine) can 
modify the protein structure by changing the number of disulphide bridges and/or 
altering hydrophobicity and charge. This can compromise protein function and 
affect intermolecular interactions with other molecules. Another less common 
form of substitution occurs when a premature stop codon is created via a point 
mutation. The result is a truncated, incomplete, and usually nonfunctional protein 
product. SNPs often occur as natural allelic variations within the population 
conferring increased risk for or protection from AMD.
 Evidence for a major inflammatory component in AMD pathology stems 
from the association of many complement proteins including CFB, complement 
component 2 (C2), and C3 with disease [89, 90]. However, the gene coding for 
CFH, a regulatory inhibitor of the AP of complement, was the first significant gene 
implicated in the pathogenesis of AMD [91-93]. In 2005, several groups identified 
a SNP, Y402H, located within the 1q32 chromosome region, corresponding to 
human CFH that was associated with AMD in several independent families. This 
provided one of the first prediction models for the prevalence and incidence of 
AMD [94]. The Y402H risk variant is associated with lifetime incidence of early 
AMD and progression from early to late stage AMD [95]. Numerous other risk 
alleles have since been identified linking CFH to AMD including rs1410996, 
rs551397, and rs900292 [96, 97]. Furthermore, mutations in genes coding for the 
complement factor H related proteins (CFHR), which bind to the central 
complement component C3b during regulation, can result in hybrid proteins with 
altered recognition domains, impairing their inhibitory function [98].
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 Changes on the long (q) arm of chromosome 10 in a region known as 
10q26 are also associated with AMD risk. The 10q26 region contains two genes 
of interest: ARMS2 and HtrA serine peptidase 1 (HTRA1). However, because of 
their close proximity, it is difficult to determine which gene is associated with AMD 
risk, or if variations in both genes contribute to disease pathology. The function of 
the protein encoded by ARMS2 has yet to be elucidated, but is thought to play a 
role in diseases of the elderly. The association of ARMS2 with AMD risk has been 
shown in numerous studies [99-102]. The ARMS2/LOC387715 SNP, A69S, is the 
most well-known polymorphism associated with AMD. Heterozygosity at ARMS2/
LOC387715 (A69A/A69S) is associated with an odds ratio (OR) of 1.69-3.0 for 
advanced AMD, while homozygosity for the risk allele (A69S/A69S) results in an 
OR of 2.20-12.1 [101]. HTRA1 encodes serine protease HTRA1, an enzyme 
involved in regulating the availability of insulin-like growth factors (IGF) by 
cleaving IGF-binding proteins. IGFs are important for the regulation of normal 
physiology by promoting cell proliferation and inhibiting apoptosis. One of the first 
studies linking HTRA1 to AMD showed that the risk allele of rs11200638 
correlated with a higher level of HTRA1 mRNA in blood lymphocytes and a 
higher level of HTRA1 protein in human RPE [46]. This correlation has since 
been replicated in archived retinas as well as fresh placenta tissues [103, 104].
The Complement System
 The complement system was first recognized in the late 19th century 
when microbiologists Paul Ehrlich, Jules Bordet, and George Nuttall discovered a 
heat-sensitive component of blood had antimicrobial activity against anthrax 
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bacilli [105-108]. They noted the antimicrobial activity of this component was 
inactivated when blood was heated above 55° C and named it “alexine.” Later 
research on guinea pigs demonstrated that the antimicrobial activity of blood was 
dependent on both heat-sensitive “alexin” and another heat-stable factor which 
we now call antibodies. In 1899, Paul Ehrlich renamed “alexin” to “complement” 
based on the fact that it complements cells of the innate immune system [107]. 
 The basic functions of complement are opsonization, chemotaxis, cell 
lysis, and agglutination. Opsonization refers to the process of marking a 
pathogen for ingestion and elimination by a phagocyte. During opsonization, an 
opsonin binds to the outer membrane of a pathogen and attracts phagocytes to 
the location. Chemotaxis describes the movement of cells toward or away from a 
chemical stimulus. This is illustrated by complement through the attraction of 
macrophages and neutrophils to sites of inflammation. Cell lysis refers to the 
rupture of a cell due to viral, enzymatic, or osmotic mechanisms which 
compromise the outer membrane, and is the end result of complement activation. 
Agglutination is defined as the clumping or clustering of pathogens into a single, 
large complex. This increases the efficiency of phagocytes, enabling them to 
eliminate more pathogens with one pass. The complement system consists of 
over 40 proteins and cell surface receptors. At sites of infection, the complement 
system is activated locally, usually through binding of an antibody to an antigen. 
This sets in motion a series of cleavages known as the complement cascade. 
Complement activation can occur via three major amplification pathways (Fig. 
1.1).
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Figure 1.1 The complement system. The three pathways of complement activation. Classical, 
lectin, and alternative pathways converge at the point of C3 activation. The lytic pathway then 
leads to the assembly of the membrane  attack complex that destroys infectious agents. 
Regulators of the alternative pathway CFH, CFI, and MCP cooperate to inactivate endothelial cell 
surface-bound C3b, thus protecting endothelial cells from complement attack. CFH, factor H; CFI, 
factor I; CFB, factor B; CFD, factor D; MCP, membrane cofactor protein [109].
 The classical pathway (CP) is antibody-dependent and is initiated when a 
molecule of C1q, the first protein in the complement cascade, binds directly to 
the surface of a pathogen or to an antibody-antigen complex. In the latter case, 
only IgM or IgG are capable of sufficient complement activation. A single 
pentameric IgM can activate the pathway, but at least two monomeric IgG 
molecules are required. C1q binding leads to conformational changes in the C1q 
molecule, enabling activation of C1r, a serine protease, which then cleaves C1s. 
The resulting C1r2s2 complex then splits C4 into C4a and C4b. C4b binds to the 
surface of the pathogen and activates C2 by cleaving it into C2a and C2b. C2b 
diffuses away while C2a remains attached to C4b, forming the classical C3 
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convertase, C4b2a. The C3 convertase cleaves C3 into C3a and C3b, which 
binds to the C3 convertase forming the classical C5 convertase, C4b2a3b. 
Formation of the C5 convertase initiates the terminal pathway described below.
 In contrast to the CP, the AP is antibody-independent and continuously 
activated at baseline, similar to a car engine idling, as a result of spontaneous C3 
hydrolysis. C3 hydrolysis occurs due to the breakdown of the internal thioester 
bond resulting in the formation of C3(H2O). C3(H2O) binds to CFB, allowing 
complement factor D (CFD) to split CFB into Ba and Bb components. Ba diffuses 
away while Bb remains attached to C3(H2O), forming the alternative C3 
convertase, C3(H2O)Bb. This compound is unstable and requires binding of 
properdin, a serum protein, which extends the half-life 10-fold. The C3 
convertase then splits C3 into C3a and C3b. C3b is capable of forming new C3 
convertase along with CFB and CFD, thus forming an amplification loop. This 
amplification loop is critical for accelerating complement attack when triggered by 
one of the other two pathways. C3b can also bind to the C3 convertase forming 
the alternative C5 convertase, C3(H2O)BbC3b, which initiates the terminal 
pathway described below. Constant control of this pathway via complement 
regulators is critical to protect the host from undesireable and potentially harmful 
complement activation [110]. 
 The lectin pathway (LP) is initiated by the binding of mannose-binding 
lectin (MBL) to mannose residues on a pathogen. IgM can also bind to antigens, 
providing a binding site for MBL [111]. MBL binding activates the MBL-associated 
serine proteases, MASP-1 and MASP-2, which cleave C4 and C2 into C4a, C4b 
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and C2a, C2b, respectively. A third serine protease, MASP-3, has been found to 
have an inhibitory affect against MASP-2 [112]. C4b and C2a then combine to 
form the classical C3 convertase. The LP then proceeds as previously described 
to form the classical C5 convertase, initiating the terminal pathway. Ficolins can 
also activate the LP by forming active complexes with mannose-binding lectin-
associated serine proteases (MASP). Structurally similar to MBLs, ficolins are 
soluble collagen-like proteins that bind to sugars on microorganisms and dying 
host cells. There are three distinct ficolins: ficolin-1 (M-ficolin), ficolin-2 (L-ficolin), 
and ficolin-3 (H-ficolin). 
 The terminal pathway describes the final stage of all three activation 
pathways. This sequence begins with the cleavage of C5 into C5a and C5b. C5a 
diffuses away while C5b remains bound to the pathogen. This is followed by the 
association of C6, forming a hydrophilic C5bC6 complex. C7 binds to C5bC6, 
resulting in a conformational change that exposes a hydrophobic site on C7 
which allows insertion of the complex into the phospholipid bilayer of the 
pathogen. C8 is a molecule made up of two proteins: C8-beta and C8-alpha-
gamma. C8-beta has a hydrophobic region which allows it to attach to the 
complex in the bilayer. The final step involves the binding of 10-15 C9 proteins 
via C8-alpha-gamma, forming a cylindrical, transmembrane pore with a diameter 
of approximately 10 angstroms. The pore, commonly known as the membrane 
attack complex (MAC), allows free diffusion of molecules both into and out of the 
cell. This may lead to osmotic imbalance through the constant flow of ions, water, 
and other small molecules along their concentration gradient, ultimately resulting 
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in cell lysis [113]. Sublytic complement activation can also occur, leading to 
NLRP3 inflammasome activation [114]. The resulting inflammatory response can 
be protective or damaging. Sublytic complement attack protects tumor cells from 
lytic doses of complement [115] and attenuates reperfusion injury through the 
formation of C5a [116], but also causes vascular endothelial growth factor 
(VEGF) secretion in RPE cells which can lead to CNV . 
 Anaphylatoxins are protein fragments produced as part of the complement 
system [117]. They can trigger degranulation of endothelial cells, mast cells, and 
phagocytes, producing a local inflammatory response. In addition, they mediate 
smooth muscle cell contraction, vascular permeability, and chemotaxis [118]. 
During the complement cascade, glycoproteins C3, C4, and C5 are cleaved into 
a- and b-fragments. The a-fragments form distinct structural domains 
approximately 76 amino acids in length and are called anaphylatoxins (i.e. C3a, 
C4a, C5a). Studies suggest that locally generated anaphylatoxins contribute to 
pathological processes in inflammatory and immunological diseases as well as 
the adaptive immune response [119].
Complement factor H
 CFH is an essential regulatory inhibitor of the alternative complement 
pathway. This protein is critical for prevention of undesirable complement 
activation on host cells and tissues, especially in the kidney. CFH has two 
primary functions: (1) decay-accelerating activity and (2) cofactor activity. CFH 
inhibits the AP through factor I-mediated inactivation of C3(H2O) or by displacing 
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Bb from the C3(H2O)Bb complex [120]. CFH is translated as a single polypeptide 
of 1,213 amino acids in length. This polypeptide chain is divided into 20 similar 
subunits, called short consensus repeats (SCR). The amino-terminus (SCRs 1-4) 
is involved in regulatory activity. CFH binds to C3(H2O) at these domains, acting 
as an antagonist for CFB, thus reducing formation of the alternative C3 
convertase. CFH is more effective when C3(H2O) residues reside on the host 
cell due to the presence of markers recognized by CFH. The carboxy-terminus 
(SCRs 19-20) is responsible for surface binding and self/non-self recognition. 
CFH binds to host markers (i.e. sialic acids and sulfated glycosaminoglycans) at 
these domains and prevents the amplification cascade of the AP, while allowing 
complement activation to proceed on pathogens lacking these markers. The 
ability of CFH to distinguish between pathogens and host cells is crucial to 
maintaining a healthy immune response. Mutations in CFH coding for these 
domains lead to activation of the AP in inherited uremic syndrome [121].
 The AP is continuously activated in the fluid phase, and tissue surfaces 
require constant complement inhibition in order to prevent cellular injury [122]. 
CFH reaches blood plasma concentrations of 500-800 µg/ml, making it the 
second most abundant plasma protein after human serum albumin [123]. Thus, 
under normal conditions, CFH is sufficient to inhibit activation of the AP. However, 
CFH seems to function differently in oxidative environments. Thurman and 
colleagues showed that treatment of ARPE-19 cells with H2O2 results in a 
decreased ability of CFH to control C3 conversion at the cell surface [124]. This 
may reflect a reduction in expression of decay accelerating factor or an inability 
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of CFH to deal with the increased C3 production. Alternatively, targeting of CFH 
to cell surfaces may be impaired in oxidative environments. Malondialdehyde 
(MDA) has been postulated to serve as a ligand on cell surfaces to recruit CFH 
and prevent complement attack [125]. After exposing ARPE-19 cells to H2O2, 
CFH is unable to bind MDA, thereby negating the inhibitory effect [126]. This 
evidence of impaired CFH targeting under oxidative conditions provide the 
rationale for using a modified CFH protein with a complement receptor 2 (CR2) 
targeting domain to circumvent the aforementioned problems.
Goals and Specific Aims
 AMD, a complex neurodegenerative disease involving genetic variants 
and environmental insults, is among the leading causes of blindness in the 
Western world. Genetic and histological evidence implicate the complement 
system in AMD pathogenesis, and smoking is the primary environmental risk 
factor associated with increased disease risk. Previous studies have shown that 
cigarette smoke exposure (CE) causes RPE defects in mice and leads to 
complement activation in patients. However, it is unknown whether complement 
activation is causative in the development of CE pathology; and if so, which 
complement pathway is required and the mechanism of action this pathway 
propagates. The primary goal of this study is to determine the role of the 
alternative complement pathway in cigarette smoke-induced ocular pathology. 
This will be examined using an AP knockout mouse to observe differences in 
visual acuity, gene expression, and retinal morphology, following chronic cigarette 
smoke exposure. The secondary goal of this study is to evaluate the feasibility of 
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the cigarette smoke model for studying AMD pathology. The efficacy of this 
model will be determined by looking for parallels between AMD pathology and 
cigarette smoke-induced ocular pathology.
 Cigarette smoke is the only proven, modifiable risk factor for AMD. 
Previous studies have shown that smoking increases the risk of developing AMD 
two- to four-fold [55]. The pathophysiology of cigarette smoke and AMD is 
complex and likely involves a number of different mechanisms. The RPE is under 
a high degree of oxidative stress from the turnover of photoreceptor OS. 
Cigarette smoke introduces many more free radicals [64] and likely contributes to 
oxidative damage loads. Smoking also depletes antioxidants (vitamin C, E, 
carotenoids  [72, 73, 127, 128], glutathione, cysteine, methylumbelliferone 
glucuronide, and ferroxidase [74, 129]), which act as natural oxidation inhibitors 
and help clear free radicals from the system. Oxidative stress has been shown to 
impair mitochondrial structure and function [130]. Lastly, cigarette smoke can 
directly cleave C3, a central constituent of the complement cascade, into C3a 
and C3b, since it modifies C3 in a way that diminishes binding to CFH [82]. C3b 
can then bind to a membrane to trigger complement activation. Importantly, the 
majority of C3b deposited on cell surfaces appears to be due to activity of the AP 
amplification loop (80-90% for CP [131] and LP [132]). Based on these 
observations, we hypothesize that CE will increase the amount of oxidative 
stress in the the RPE, resulting in dysfunctional mitochondria, impaired retinal 
pigment epithelium-Bruch’s membrane-choriocapillaris (RPE-BrM-CC) complex 
structure and function, and ultimately decreased visual function. Furthermore, we 
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hypothesize that the AP of the complement system contributes to in CE 
pathology and that inhibition of this pathway is protective. This hypothesis will be 
tested by the following specific aims. Aims 1 and 2 will be discussed together in 
Chapter 2, while Aim 3 will be discussed in Chapter 3.
Specific Aim 1. Determine behavioral, functional, and morphological 
deficits associated with long-term cigarette smoke 
exposure in WT mice.
Specific Aim 2. Determine whether AP activation is required for the 
development of CE pathology.
Specific Aim 3. Determine whether smoke-induced ocular pathology is 
amenable to anti-complement-based therapy.
 There is growing evidence linking oxidative stress and smoking, as well as 
complement activation to the development and progression of AMD. Our studies 
examine the role of the AP of complement in CE-induced AMD pathology. The 
proposed experiments offer insight into the role of complement in the 
development of AMD and suggest that behavioral, functional, and morphological 
deficits may be amenable to complement based therapy. A better understanding 
of the complement pathway is critical to the development of novel therapeutics 
and treatment of this macular dystrophy. 
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CHAPTER 2




 AMD is one of the leading causes of blindness in the elderly among 
Western populations. AMD is a common, late-onset maculopathy that can be 
diagnosed in one of two forms: atrophic, “dry”; or neovascular, “wet” [133]. The 
atrophic form of the disease is best characterized by the presence of deposits 
rich in lipoprotein known as drusen (≥63 µm in size) in the subretinal space 
between BrM and the RPE in the macular region of the eye, and may also be 
associated with pigmentary abnormalities. These alterations can be easily 
visualized in patients through fundoscopic imaging. The neovascular form is 
typically associated with proliferation of the choroidal blood vessels through BrM 
into the subretinal space. These vessels then leak blood and proteins either into 
the subretinal or sub-RPE space [134], leading to increased photoreceptor cell 
death. Although patients can be diagnosed with either form of the disease, the 
atrophic form is the most common, making up 90 percent of all cases [2].
 AMD is a complex, multifaceted disease that is influenced by genetic and 
environmental factors. Several of the main genetic risk factors are 
polymorphisms occurring in complement genes, including the AP inhibitor, CFH 
[91-93, 135], CFB [89], C2 [89], and C3 [89, 90]. Several of these complement 
components have been found to be associated with pathological features of 
AMD. Drusen present in donor eyes of patients with confirmed dry AMD, contain 
complement components, beta-amyloid, and other inflammatory factors [136]. 
AP components and inhibitors as well as C3 have been shown to localize to the 
RPE, BrM, and choroid in humans [137]. This same tissue is also immunopositive 
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for MAC proteins, and it appears that MAC immunoreactivity is correlated with 
AMD severity and loss of RPE cells [138]. Furthermore, genotype-phenotype 
correlations have revealed associations between CFH risk alleles. Alleles that 
generate less effective CFH [139] result in peripheral drusen of increased size 
and reticular pigment [140, 141]. Conversely, the protective allele of CFB, which 
is a less efficient activator of the AP [142], is associated with smaller drusen and 
a reduced area covered by those drusen [143]. Taken together, there appears to 
be a correlation between the degree of pathology and amount of activation in the 
AP of complement.
 The complement cascade is an integral part of the innate immune system, 
as it “complements” the ability of antibodies to clear pathogens or other “non-self” 
cells from an organism. There are three initiation pathways (classical, lectin, and 
alternative) involved, that all lead to a common terminal pathway [144]. The CP is 
initiated when C1q, a pattern recognition molecule complex, binds to the surface 
of a pathogen or to an antibody:antigen complex. The LP can be initiated by the 
binding of a complex between MBL and MASP or ficolin, and MASP to mannose-
containing carbohydrates on bacteria, viruses, or unprotected cell surfaces. The 
AP is activated when either a spontaneously generated C3b molecule or one 
generated by either the CP or the LP binds to the surface of a pathogen or 
unprotected cell surfaces. All three pathways converge by forming a protease 
called C3 convertase, triggering the common terminal pathway. This final 
pathway is involved in executing the basic functions of the complement system. 
Convertase activity generates soluble anaphylatoxins involved in attracting 
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macrophages and neutrophils, as well as cell-bound opsonins involved in 
removal of pathogens and cells. Finally, MAC formation, by virtue of its ability to 
form a non-specific pore in the cell membrane, is involved in cell lysis. Important 
for our study, the AP also provides an amplification loop for the CP and LP such 
that over 80% of C3 convertase deposited onto cells is derived from AP 
activation rather than the initiating pathway [131, 132]. Given the destructive 
capacity of the complement cascade, this system is tightly regulated by a number 
of inhibitors expressed by the host cells. These inhibitors include both cell-
attached as well as soluble inhibitors that prevent complement activation on 
healthy self-cells. However, the levels as well as the cellular localization of these 
inhibitors are influenced by environmental factors, including oxidative stress [145] 
or cigarette smoke [146, 147].
 Cigarette smoke is the only proven, modifiable risk factor for AMD. 
Previous studies have shown that smoking increases the risk of developing AMD 
2–4-fold [55]. In addition, smoking also promotes the progression of AMD from 
the atrophic to neovascular form [56]. This progression may occur up to 10 years 
earlier in smokers compared to non-smokers [53]. However, cessation has been 
shown to reduce the risk of developing AMD and progression to the neovascular 
form [148]. The pathophysiology of cigarette smoke and AMD is complex and 
likely involves a number of different mechanisms. The RPE is under a high 
degree of oxidative stress from the turnover of photoreceptor OS. Cigarette 
smoke introduces many more free radicals [64] and likely contributes to oxidative 
damage loads. Smoking also depletes antioxidants (vitamin C, E, carotenoids 
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[72, 73, 127, 128], glutathione, cysteine, methylumbelliferone glucuronide, and 
ferroxidase [74, 129]) which act as natural oxidation inhibitors and help clear free 
radicals from the system. Cigarette smoke can directly activate C3, the primary 
constituent of the complement cascade, since it modifies C3 in a way that 
diminishes binding to CFH [82]. Lastly, nicotine found in cigarette smoke exerts a 
vasoconstrictive action via α-adrenergic receptor activation which reduces 
choroidal blood flow [149]. This reduction in choroidal circulation may underlie 
depositions in BrM due to inefficient clearance of debris from the RPE [42]. Taken 
together, although smoking increases the risk of AMD and leads to complement 
activation, there is no conclusive evidence that smoking-related pathology is the 
result of complement activation.
 Given the aforementioned lines of evidence, we tested whether pathology 
is dependent upon complement activation by exposing mice to long-term 
cigarette smoke. Previous studies using the same model have documented 
activation of the terminal pathway of the complement system in the RPE and 
choroid, concomitant with damage to the RPE and photoreceptors [66, 70, 
150-152]. However, little is known concerning which complement pathway might 
be involved. In the present study we investigated the role of the AP. We 
hypothesized that AP-deficient mice would be protected from smoke-induced 
deficits based on the observation that the majority of C3 activated on cell 
surfaces appears to be due to activity of the AP amplification loop (80–90% for 




 CFB −/− mice on a C57BL/6J background were generously provided by V. 
Michael Holers (University of Colorado Health Science Center, Denver, CO). 
C57BL/6J (also referred to as WT) mice were purchased (Jackson laboratory, 
Bar Harbor, ME) [153]. Mice were confirmed to be negative for the RD8 locus by 
PCR using published primers (Fig. 2.1). See Appendix for details. Animals were 
housed under a 12:12 h, light:dark cycle with access to food and water ad 
libitum.
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 For electroretinography (ERG) or OCT imaging, mice were anesthetized 
using intraperitoneal injections of xylazine and ketamine (20 and 80 mg/kg, 
respectively), and pupils were dilated (2.5% phenylephrine HCl and 1% atropine 
sulfate). Hydroxypropyl methylcellulose (GenTeal, 0.3%) was used as an 
adherent for the contact lens electrode or was applied regularly throughout the 
imaging process to maintain corneal hydration. All experiments were approved by 
the Medical University of South Carolina Institutional Animal Care and Use 
Committee and performed in accordance with the Association for Research in 
Figure 2.1 Genotyping for CFB and RD8 in WT and CFB −/− mice. DNA was isolated 
from WT and CFB −/− mice, amplified with PCR primers, and resolved on a 1.5% agarose 
gel containing ethidium bromide for one hour. Gels were visualized under UV light. (A) PCR 
primers for complement factor B (CFB) were used to confirm the presence or absence of 
CFB. Lane 1 represents a GeneRuler 100 bp Plus DNA ladder. Amplified DNA samples 
from WT mice reveal a band at 748 bp which corresponds to the Amplicon CFB wild type 
allele (lane 2), whereas CFB −/− mice reveal a band at 610 bp which corresponds to the 
CFB knockout allele (lane 3). (B) PCR primers for RD8 were used to confirm that both 
genotypes were RD8 positive. Lane 1 represents a 50 bp HyperLadderV. Amplified DNA 
samples from WT mice reveal a band at 220 bp which corresponds to the Amplicon RD8 
wild type allele (lane 2) and no RD8 mutant band (lane 3). Amplified DNA samples from 
CFB −/− mice show the same genetic profile (lane 4, 5).
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Vision and Ophthalmology statement for the use of animals in ophthalmic and 
vision research.
Exposure to Cigarette Smoke
 Eight-week-old C57BL/6J and CFB −/− male mice were divided into two 
groups (n = 12 per group and genotype). The control group was kept in a filtered 
air environment, and the experimental groups were subjected to cigarette smoke. 
CE was carried out (5 hours per day, 5 days per week) by burning 3R4F 
reference cigarettes (University of Kentucky, Louisville, Kentucky, USA) using a 
smoking machine (Model TE-10; Teague Enterprises) for 6 months. The average 
concentration of total suspended particulates was 130 mg/m3 and was monitored 
twice daily.
Electroretinography
 ERG recordings and data analyses were performed as previously 
described [81] using the EPIC-2000 system (LKC Technologies, Inc.). In short, 
mice were dark-adapted overnight prior to testing. ERG responses were obtained 
using light stimuli with varying light intensities and wavelengths. Under scotopic 
conditions, responses to 10 µs single-flashes of white light (maximum intensity of 
2.48 cd m−2) between 40 and 0 db of attenuation were measured. After light-
adapting animals for 2 min with rod-saturating light [154], UV-cone responses 
were tested using LED flashes centered at 360 nm. Peak a-wave amplitude was 
measured from baseline to the initial negative-going voltage, whereas peak b-




 Visual acuity and contrast sensitivity of mice were measured by observing 
their optomotor responses to moving sine-wave gratings (OptoMotry) as 
previously described [155]. Mice reflexively respond to rotating vertical gratings 
by moving their head in the direction of grating rotation. To observe these 
movements, mice were placed individually on the central elevated pedestal 
surrounded by a square array of computer monitors that display stimulus 
gratings. Mice were monitored via an overhead closed-circuit TV camera that 
allowed the observer to view only the central platform and not the rotating 
grating. Mice were allowed to adjust to the chamber for 2 min with the monitors 
displaying a 50% gray uniform field prior to testing, and monitors returned to a 
homogenous gray between trials. All tests were conducted under photopic 
conditions with a mean luminance of 52 cd m−2. Visual acuity was measured by 
finding the spatial frequency threshold of each animal at a constant speed (12 
deg/s) and contrast (100%) with a staircase procedure that systematically 
increased the spatial frequency of the grating until the animal no longer exhibited 
detectable responses. Contrast sensitivity was determined by taking the 
reciprocal of the contrast threshold at a fixed spatial frequency (0.131 cyc/deg) 
and speed (12 deg/s). It has previously been determined that this spatial 
frequency falls within the range of maximal contrast sensitivity for 9-month-old 
C57BL/6J mice (data not shown). Contrast of the pattern was decreased 
systematically in a staircase manner until the animal stopped responding.
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Quantitative RT-PCR
 RPE/choroid/sclera (henceforth referred to as RPE/choroid) and retina 
fractions were isolated from control and smoke-exposed animals and stored at 
−80°C until they were used. Quantitative RT-PCR (QRT-PCR) analyses were 
performed as previously described in detail [156]. In short, real-time PCR 
analyses were performed in triplicate in a GeneAmp® 5700 Sequence Detection 
System (Applied Biosystems) using standard cycling conditions. Quantitative 
values were obtained by the cycle number, normalizing genes of interest to β-
actin, and determining fold difference between room air and CE within 
genotypes. Fold difference values were compared using Z-test analyses, 
accepting a significance of P<0.05. See Table 2.1 for a full list of primers used for 
QRT-PCR.
Table 2.1 Quantitative QRT-PCR primer sequences. Forward and reverse primers are listed for 
each gene assayed along with the associated symbol. Hemolytic complement is also known as 
complement component 5, C5. Serine (or cysteine) peptidase inhibitor, clade F, member 1 is also 
known as pigment epithelium-derived factor, PEDF.
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 SD-OCT was performed using a Bioptigen Spectral Domain Ophthalmic 
Imaging System (Bioptigen Inc., Durham, NC). The system is equipped with a 
probe and platform designed for mice that allows for easy orientation and 
alignment of the central retina.
 Imaging and data analysis were performed with Bioptigen® InVivoVue 
software. Rectangular volume scans were taken in the nasal quadrant from the 
optic disc, each volume consisting of 33 B-scans (1,000 A-scans per B-scan). 
Five separate scans were collected and averaged to generate a high resolution 
image. Vertical calipers were placed to measure the ONL and inner nuclear layer 
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(INL) for each scan. All measurements were taken 500 µm from the optic disc. 
Data reflects the average of both eyes per animal.
Tissue Preparation
 The eyes were enucleated, and a slit was cut into the cornea to allow for 
rapid influx of fixative. Eyes were fixed overnight in 2.5% glutaraldehyde, 1% 
formaldehyde, 3% sucrose, and 1 mM MgSO4 in 0.1 M cacodylate buffer, pH 7.4. 
The eyes were then dissected and small central portions were osmicated for 60 
minutes in 0.5% OsO4 in 0.1 M cacodylate buffer, processed in maleate buffer for 
en bloc staining with uranyl acetate, dehydrated in graded ethanols, and 
processed for resin embedding as in [157]. Serial sections were cut at 90 nm on 
a Leica Ultramicrotome onto carbon-coated Formvar® films supported by nickel 
slot-grids.
Ultrastructural Analysis
 Transmission electron micrographs (EM) were captured using a JEOL 
JEM 1400 transmission electron microscope using SerialEM software to 
automate image capture overnight with 1200–1500 images captured per section, 
yielding datasets that were then processed with the NCR Toolset [158, 159] to 
generate image mosaics with corrections for image aberrations induced by 
electron microscopy.
 Electron microscopy images were evaluated using Adobe® Photoshop® 
and ImageJ software. For each animal, two RPE cells were outlined using the 
apical processes and the basal lamina (thickness) as well as the basolateral 
walls (length) as borders. A masking-layer for all mitochondria present within an 
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RPE cell was created to calculate average mitochondrial number and size. To 
determine mitochondrial position, the centroid coordinates for each 
mitochondrion was calculated as a percentage of the corresponding RPE length 
and thickness, respectively. Coordinates were assigned to basolateral, basal, 
central, or apical compartments based on normalized X-Y coordinates. The 
density of basal laminar (BL) infoldings was determined by dividing the area 
occupied by individual infoldings, by the total BL area for each of the two RPE 
cells. The BL area was isolated for each RPE cell in Photoshop®. Images were 
binarized, processed using a median filter (10 px radius) to reduce background 
noise, and analyzed for area measurements. BrM thickness was determined by 
analyzing ~13 µm mean length of BrM adjacent to each of the outlined RPE cells. 
A masking layer was created over the ICL along each segment of BrM using 
RPE-BrM and the middle elastic layer (MEL) as boundaries. The area of the 
masking layer was divided by the length of the segment to determine an average 
BrM ICL thickness. For OS width, eight OS were randomly sampled from each 
animal, measuring the width at the thickest point and calculating an average. 
Müller cell percent area was determined by subtracting the area occupied by the 
rod/cone somas in a ~600 µm2 area of the ONL and dividing by the total area 
analyzed; using the same masking technique as described from BrM thickness 
analysis.
 Mitochondrial distribution profiles were generated by performing a percent 
normalization on the coordinates of centroids for all mitochondria with respect to 
the length/width of the RPE cell they were imaged from. After plotting the data, 
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we assigned each mitochondrion to one of 4 bins as follows: basolateral (x-value 
<0.20 or x-value >0.80), basal (0.20≤ x-value ≤0.80 and y-value <0.33), central 
(0.20≤ x-value ≤0.80 and 0.33≤ y-value <0.66), and apical (0.20≤ x-value ≤0.80 
and 0.66≤ y-value <1). Significance values were based on the percentage of 
mitochondria that fall into each bin.
Immunohistochemistry
 Paraffin-embedded mouse eyes were sectioned at 5 µm and 
immunostained for the presence of complement deposition using an antibody 
(Ab) to C3, split-fragment C3d (R&D Systems, Volcano, CA). 
Immunohistochemistry staining was performed as previously described [160]. In 
brief, primary-Ab binding was visualized using the Vector Laboratories 
ImmunoEdge detection kit and diaminobenzidinechromogen development 
(Vector Laboratories, Burlingame, CA). Specificity of staining was assessed by 
omission of primary Ab and the use of isotype controls. To assess the cellular 
and spatial localization of C3d immunostaining, eye sections were pretreated in 
30% hydrogen peroxide for 18 hours to bleach melanin deposits prior to 
immunostaining, as previously described [161].
Statistics
 For data consisting of multiple groups, repeated measures analysis of 
variance (ANOVA) followed by the Fisher post hoc test (P<0.05) was used; single 
comparisons were analyzed using the Student t-test assuming equal variance 
(P<0.05; Statview; SAS Institute, Inc.). Fold changes in QRT-PCR experiments 
were analyzed using a Z-test (P<0.05).
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Results
Effect of AP Deficiency on Smoke-Induced Impairment of Visual Function
 Dry AMD in patients is associated with thickening of BrM that can 
eventually lead to photoreceptor degeneration [162, 163]. Even without cell loss, 
the structural changes in BrM can lead to impaired nutrient exchange between 
the choroid and the RPE (reviewed in [164]), as well as a reduction in the 
generation and delivery of the vitamin-A-based chromophore, 11-cis retinal, to 
the photoreceptor outer segments [165]. In patients, these AMD-associated 
pathologies lead to a reduction in visual function as measured by ERG, as well 
as changes in visual acuity and contrast sensitivity.
 Here, ERG recordings were assessed to determine the impact of 6 
months of CE on mouse retinal function. ERG responses were analyzed under 
dark-adapted, scotopic conditions to determine rod photoreceptor function, as 
well as under photopic conditions after light-adaptation, to determine cone 
function. Here, the focus was on the mouse UV-cones, which have been shown 
to be more susceptible to perturbations (summarized in [166]) and can be 
isolated spectrally by ERG. For both scotopic and photopic ERGs, the b-wave 
amplitudes were reported, which are a mass potential generated by the bipolar 
cells that sum photoreceptor output (reviewed in [167]). Six months of CE caused 
an overall reduction in scotopic ERG amplitudes in WT animals (P<0.001) (Fig. 
2.2A). While the b-wave responses of the smoke-exposed animals were 
marginally reduced when compared to non-exposed controls at lower light 
intensities (40, 30 dB), the differences reached significance at higher stimulus 
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intensities (20, 10, 6, 0 dB; P<0.05). Likewise, the maximum UV-cone response 
after CE was reduced in WT mice by ~30% (P<0.001). The photoreceptor cell 
response (a-wave), which drives the b-waves, was equally affected (data not 
shown). In contrast, photoreceptor cell function was significantly preserved in 
smoke-exposed CFB −/− mice (P = 0.5), irrespective of whether rod or UV-cone 
function was assessed (Fig. 2.2B). However, while rod ERG amplitudes have 
previously been found not to differ between age-matched WT and CFB −/− mice 
at 3-months-of-age [81], both rod and cone ERG amplitudes are reduced by 20–
30% across all light intensities by 9-months-of-age (P<0.01) (Fig. 2.3).
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Figure 2.2 Electroretinography analysis for WT and CFB −/− mice following CE. 
ERG recordings were performed in cohorts of age-matched WT (A) and CFB −/− (B) 
mice exposed to 6 months of cigarette smoke (CE) or room air. Dark-adapted, 
scotopic ERGs were recorded in response to increasing light intensities, and light-
adapted photopic UV-cone ERGs to a single, maximum light intensity. Scotopic ERGs 
were analyzed using multiple ANOVA, followed by comparison of individual light 
intensities using t-test analyses. WT mice exposed to smoke had significantly lower 
dark-adapted b-wave amplitudes compared to controls (P<0.001), in particular at 
higher light intensities (20, 10, 6, 0 dB). Impairment in cone function is evidenced by 
the reduction in maximum UV-cone b-wave amplitudes. In comparison, ERG 
amplitudes in both scotopic and photopic ERGs were unaffected in AP-deficient mice 
exposed to smoke. Photoreceptor cell responses (a-waves), which drive the b-waves, 
were equally affected (data not shown). Data are expressed as mean ±SEM (n = 6-8 
per condition; *, P<0.05; **, P<0.001).
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 To correlate the ERG findings with a behavioral measure of visual acuity, 
we performed optokinetic response (OKR) tests to determine spatial frequency 
(Fig. 2.4A) and contrast sensitivity (Fig. 2.4B) under photopic light conditions. 
While spatial acuity and contrast sensitivity are influenced by both inner and 
outer retina function, both measures have been shown to correlate with 
photoreceptor cell function. Spatial acuity, which in rodents is low due to spatial 
summation, can be observed after RPE [168] or photoreceptor cell damage 
[169]. Likewise, loss of contrast sensitivity is a manifestation of photoreceptor cell 
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Figure 2.3 Electroretinography analysis for WT and CFB −/− mice at baseline. 
ERG recordings were performed in cohorts of age-matched WT and CFB −/− mice 
exposed to room air for 6 months. Dark-adapted, scotopic ERGs were recorded in 
response to increasing light intensities, and light-adapted photopic UV-cone ERGs to 
a single, maximum light intensity. Using multiple ANOVA, CFB −/− mice had lower dark-
adapted b-wave amplitudes compared to WT mice (P<0.05), although when individual 
light intensities were compared by t-test analysis, significance was only obtained at 
the highest light intensity (0 dB), suggesting that rod function is largely intact. 
However, cone function does appear to be impaired in CFB −/− mice as evidenced by 
the reduction in maximum UV-cone b-wave amplitude. Photoreceptor cell responses 
(a-waves), which drive the b-waves, were equally affected (data not shown). Data are 
expressed as mean ±SEM (n = 6-8 per condition; *, P<0.001)
loss in retinal degenerate mice (rd10) [170] or the Royal College of Surgeons rat 
[171]. Spatial frequency threshold (spatial acuity) in WT mice after CE did not 
differ from that of control animals exposed to room air (0.34±0.01 cyc/deg versus 
0.37±0.01 cyc/deg; n.s.). Spatial frequency threshold was slightly lower in CFB −/− 
control mice (0.31±0.01) than in WT controls (P<0.001); but just as in WT 
animals, CFB −/− mice were unaffected by CE (0.33±0.00; P>0.05). Contrast 
sensitivity on the other hand was affected by smoke inhalation. A robust 
decrease in contrast sensitivity was observed for the WT smoke-exposed group 
(7.16±0.37) compared to controls (18.34±1.00; P<0.01). As for the remaining 
visual function tests, contrast sensitivity threshold was lower for CFB −/− control 
mice (9.48±1.22) when compared to WT controls (P<0.001), but the levels were 
unaffected by CE (10.78±0.61; P = 0.34).
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Figure 2.4 CE does not affect visual acuity, but impairs contrast sensitivity. 
Optomotor responses were analyzed in WT and CFB −/− mice after exposure to 6 
months of cigarette smoke (CE) or room air. (A) Visual acuity was measured by 
identifying the spatial frequency threshold at a constant speed (12 deg/sec) and 
contrast (100%). Spatial frequency thresholds were not affected by treatment, although 
a genotype-dependent difference in visual acuity was identified (WT versus CFB −/− at 
room air, P<0.001). (B) Contrast sensitivity was measured by taking the reciprocal of 
the contrast threshold at a fixed spatial frequency (0.131 cyc/deg) and speed (12 deg/
sec). We previously determined that this spatial frequency falls within the range of 
maximal contrast sensitivity for 9-month-old WT mice (data not shown). WT mice after 
CE showed a significant reduction in contrast sensitivity compared to controls, while 
AP-deficient mice remained unchanged. As for visual acuity, contrast sensitivity was 
affected by genotype (P<0.001), with CFB −/− mice being significantly less sensitive. 
Data are expressed as mean ±SEM (n = 3-9 per condition; *, P<0.01).
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Effect of AP Deficiency on Smoke-Induced Changes in Gene Expression
 To gain further insight into how CE might be affecting visual function, QRT-
PCR was performed for a wide range of genes that fall into one of six categories: 
photoreceptor cell function, complement activation, control of angiogenesis, 
oxidative stress, autophagy, and mitochondrial function. With the exception of rod 
and cone opsin gene levels, which were determined in retina samples, all other 
genes reflected changes in the RPE/choroid fraction. The fold-difference between 
room-air and smoke-exposed animals are plotted for WT (Fig. 2.5A) and CFB −/− 
mice (Fig. 2.5B).
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Figure 2.5 Gene expression changes in ocular tissues between WT and CFB −/− 
mice following CE. Analysis of marker gene expression in WT (A) and CFB −/− (B) 
mice, using quantitative RT-PCR on cDNA generated from RPE/choroid/sclera fraction 
and retina. Quantitative values were obtained by cycle number (Ct value), determining 
the difference between the mean experimental and control (Actb) ΔCt values for 
cigarette smoke (CE) versus room-air-exposed mice within each genotype (fold 
difference). Candidates were examined from a number of categories including 
photoreceptor cell function (Rho, Opn1sw, Opn1mw, Rpe65), complement activation 
(C3, Cfb, Cfd, Cfh, Cd55, Cd59a), control of angiogenesis (Vegfa, Serpinf1), oxidative 
stress (Hif1a, Cp), autophagy (Lyz1, Lamp2, Klc3), and mitochondrial function (Mfn1, 
mt-Co1, Dnm1l, Ndufb8, Pfkfb1, Hmox1). Significant changes were identified in all six 
categories for WT mice, suggesting decreased cone function and chromosphere 
production, increased complement activation, the generation of a pro-angiogenic, and 
oxidative environment with impaired repair processes (autophagy) and reduced energy 
production under CE conditions. In comparison, gene expression was minimally 
affected in CFB −/− animals. Data are expressed as mean ±SEM (n = 3 per condition; *, 
P<0.05).
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 In WT mice, CE significantly altered gene expression levels for genes 
belonging to all six categories. First, since CE reduced ERG-amplitudes and 
contrast sensitivity, levels of the genes encoding for the apoproteins of the 
photopigments as well as the rate-limiting enzyme for the production of the 
chromophore required for all pigments, RPE65, were examined. With the 
exception of rhodopsin (Rho), all photoreceptor function genes were significantly 
downregulated (short- and middle-wavelength cone opsins, Opn1sw; Opn1mw; 
Rpe65). Second, CE has been shown to increase complement activation in the 
mouse RPE [150]. Here, we find significant changes in gene expression in the 
RPE/choroid following CE for complement genes, including increases in essential 
components of the alternative and terminal complement pathway, CFB and C3; 
and a decrease in complement inhibitors, CFH, CD55, and CD59. Third, smoking 
is associated with edema, which in the RPE is controlled by two factors: the pro-
angiogenic factor, VEGF (Vegfa), and the anti-angiogenic factor, pigment 
epithelium-derived factor (PEDF [Serpinf1]) [172]. Vegfa was found to be 
significantly elevated, whereas Serpinf1 showed a robust decrease of over 30-
fold. Fourth, smoking produces carbon monoxide, which binds to hemoglobin, 
reducing oxygen availability, resulting in hypoxia. Here, we found that markers of 
oxidative stress, including the hypoxia-inducible transcription factor, Hif1a, and 
the ferroxidase enzyme, ceruloplasmin (Cp), were upregulated in the RPE/
choroid of smoke-exposed mice. Fifth, autophagy is a basic catabolic process 
designed to remove damaged proteins and organelles expected to result from 
CE. Autophagy genes in the RPE were downregulated under smoking conditions, 
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with significant differences found for lysozyme 1 (Lyz1), lysosomal-associated 
membrane protein 2 (Lamp2), and microtubule-associated protein 1 light chain 3 
alpha (Map1lc3a). Sixth, an increase in mitochondrial number and decline in 
mitochondrial function has been reported in response to tobacco smoke [173]. In 
support of mitochondrial stress and biogenesis, we found a significant increase in 
mitochondrial genes in the RPE/choroid affecting mitochondrial fission and fusion 
(mitofusin 1, Mfn1; dynamin 1-like, Dnm1l); an increase in mitochondrial 
respiratory proteins (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8, 
Ndufb8, mitochondrially encoded cytochrome c oxidase I, mt-Co1), as well as a 
decrease in protective response gene heme oxygenase (decycling) 1 (Hmox1). 
Finally, 6-phosphofructo-2-kinase/fructose-2,6-bi phosphatase1 (Pfkfb1), the rate 
limiting enzyme in glycolysis, was found to be upregulated, potentially increasing 
ATP production via glycolysis.
 In CFB −/− mice, CE had minimal effects on retina and RPE/choroid gene 
expression. No differences were observed in mRNA levels of genes involved in 
photoreceptor cell function, complement activation or autophagy under CE 
conditions when compared to controls. Significant changes were observed in 
genes controlling angiogenesis (Vegfa, Serpinf1), oxidative stress (Hif1a) and 
mitochondrial function (Mfn1, Dnm1l, Ndufb8, and Hmox1); however, the fold 
changes were smaller than those in WT mice (5–84% of WT levels with a median 
of 31%). Since functional differences were observed by ERG and OKR between 
WT and CFB −/− mice, gene expression was compared between genotypes 
without CE (Fig. 2.6). At 9 months-of-age, expression of opsin genes was 
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increased, but levels of Rpe65 were significantly lower. In the absence of CFB, 
levels of CFD were found to be significantly elevated, whereas angiogenesis and 
autophagy genes were not altered in a consistent manner. Finally, changes in 
mitochondrial gene expression were observed, with a reduction in Mfn1, Dnm1l, 
Ndufb8, and Hmox1 along with an increase in Hif1a.
 Since most complement components are generated in the liver, and many 
effects of complement activation are thought to be caused by systemic increases 
Figure 2.6 Differences in ocular gene expression between WT and CFB −/− mice 
at baseline. Analysis of marker gene expression in WT and CFB −/− mice, using 
quantitative RT-PCR on cDNA generated from RPE/choroid/sclera fraction and retina. 
Quantitative values were obtained by cycle number (Ct value), determining the 
difference between the mean experimental and control (Actb) ΔCt values for CFB −/− 
versus WT mice exposed to room air (fold difference). Candidates were examined 
from a number of categories including photoreceptor cell function (Rho, Opn1sw, 
Opn1mw, Rpe65), complement activation (C3, Cfb, Cfd, Cfh, Cd55, Cd59a), control of 
angiogenesis (Vegfa, Serpinf1), oxidative stress (Hif1a, Cp), autophagy (Lyz1, Lamp2, 
Klc3), and mitochondrial function (Mfn1, mt-Co1, Dnm1l, Ndufb8, Pfkfb1, Hmox1). 
Significant differences were identified in all six categories for CFB −/− mice, suggesting 
increased cone function and reduced energy production compared to WT animals. 
Data are expressed as mean ±SEM (n = 3 per condition; *, P<0.005; **, P<0.001).
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in complement activation, gene expression of C3, complement component 5 
(C5), and complement component 9 (C9), as well as AP components CFB and 
complement factor properdin (Cfp), were analyzed in livers from CE mice. With 
the exception of C9, gene expression of all other components was significantly 
elevated in WT mice (Fig. 2.7).
Effect of AP Deficiency on Smoke-Induced Histological Changes
 Given the functional and behavioral deficits described above, animals 
were examined using in vivo OCT imaging to determine the thickness of various 
retinal layers (Fig. 2.8AB, EF). This was followed up with histological analyses by 
light microscopy (Fig. 2.8CD, GH) and electron microscopy (see the following 
Figure 2.7 Gene expression changes in WT liver following CE. Analysis of 
complement gene expression in WT mice, using quantitative RT-PCR on cDNA 
generated from liver. Quantitative values were obtained by cycle number (Ct value), 
determining the difference between the mean experimental and control (Actb) ΔCt 
values for cigarette smoke (CE) versus room-air-exposed WT mice (fold difference). 
Complement components C3 and C5 (hemolytic complement, Hc) were significantly 
elevated along with AP activators Cfb and Cfp, whereas C9 remained unchanged. 
Data are expressed as mean ±SEM (n = 3 per condition; *, P<0.001).
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sections). Representative OCT images are presented for WT and CFB −/− mice 
under CE and room-air conditions, together with corresponding retinal tissue 
sections. There was noticeable thinning of the ONL and INL layer following CE in 
C57BL/6J animals that was readily observed in both OCT and epon sections. 
This change was not observed in CFB −/− mice.
 The OCT images were analyzed, using hyper-reflective bands to mark the 
beginning and end of each retinal layer of interest, as previously described [174]. 
Figure 2.8 Optical coherence tomography and histological sections from WT and CFB −/− 
mice following CE. Posterior poles from WT (A-D) and AP-deficient (E-H) mice were analyzed 
in vivo using OCT (A,B and E,F) and ex vivo using histology (C,D and G,H), comparing 
cigarette smoke (CE) and control conditions. OCT measurements were taken ~0.5 mm from 
the optic nerve head in the nasal quadrant. There is visible thinning of the ONL (red) and INL 
(blue) in WT animals that is absent in CFB −/− mice. Light microscopy performed on epoxy 
sections of central retina, derived from WT and CFB −/− animals, supports the thinning 
observed in OCT images for WT mice exposed to smoke.
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We confirmed that there is a thinning of the ONL and INL in WT animals exposed 
to smoke when compared to age-matched controls (ONL: 53.04±0.57 versus 
47.84±0.08; INL: 24.18±0.27 versus 21.41±0.72; P<0.03). In contrast, the slight 
reduction in ONL and INL thickness observed in CFB −/− mice was not found to 
be statistically significant (ONL: 57.78±0.41 versus 51.95±0.64; INL: 24.29±0.49 
versus 23.83±0.24; n.s.). ONL and INL thickness, however, did not differ between 
genotypes when animals were raised in room air.
Ocular Localization of C3d After CE
 To correlate ocular pathologies with complement activation, we analyzed 
the localization of the complement activation product, C3d, a covalent cell 
membrane-attached breakdown product of C3 using immunohistochemistry. C3d 
was found to be deposited in RPE/BrM and choroid in WT mice exposed to 
smoke (Fig. 2.9B), but not in control animals (Fig. 2.9A). No immunoreactive 
material was found in the retina. Staining was attenuated in CFB −/− mice 
exposed to smoke (Fig. 2.9D), whereas the CFB −/− mice raised in room air were 
C3d negative (Fig. 2.9C).
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Lack of AP Abolishes Disruption of RPE-BrM Morphology Caused by CE
 In order to gain a better understanding of the ultrastructural deficits that 
underlie our AMD model, we analyzed EMs based on a number of different 
criteria. These include RPE cell morphology, BrM thickness, IS/OS length, and 
Müller cell area. Representative EMs for WT mice (Fig. 2.10AB) and CFB −/− 
mice (Fig. 2.10CD) under control and CE conditions were depicted. BrM is a 
pentalaminar structure, consisting of the basement membrane of the RPE, the 
Figure 2.9 C3d deposition in eyes exposed to smoke. Localization of the complement 
activation product, C3d, one of the C3 opsonins that binds covalently to (cell) membranes 
was identified using immunohistochemistry, comparing WT (A,B) or CFB −/− mice (C,D) 
exposed to room air (A,C) or cigarette smoke (CE) (B,D). Intense C3d immunoreactivity 
(brown deposits) was seen in RPE/BrM and choroid in smoke-exposed WT mice when 
compared to controls. In mice lacking the AP tick-over mechanism and amplification loop, 
reduced staining was observed in RPE/BrM and choroid after CE, whereas those animals 
exposed to room air demonstrated no immunoreactivity. Please note that in order to 
perform labeling in the pigmented RPE and choroid, melanin was bleached, resulting in 
faint pigmentation and revealing the nuclei of the RPE.
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inner collagenous zone, the middle elastic layer, the outer collagenous zone, and 
the basement membrane of the choriocapillaris. Overall, BrM was remarkably 
thicker in smoke-exposed WT animals when compared to controls raised in room 
air. The typical pentalaminar structure of BrM was in disarray because the MEL 
can no longer be distinguished in the smoke condition. Also, note the large 
deposits in the outer collagenous layer (OCL; asterisks) in BrM that are absent in 
the controls. These deposits were associated with lower fenestration density 
(arrows) in the choriocapillaris. These fenestrations are responsible for shuttling 
nutrients and waste across BrM between the RPE and choroid. In comparison, 
fenestrations were dispersed evenly along the choriocapillaris in control animals. 
Finally, mitochondria (insets) appeared to display a damaged phenotype under 
smoke conditions. The outer membrane was not clearly defined and the cristae 
appeared disorganized. In comparison, CFB −/− mice displayed none of the 
smoke-induced distortions in RPE morphology that were identified in the WT 
animals. BrM was found to remain intact, exhibiting the identifiable 5 layers, 
without any apparent thickening. There were no deposits found in BrM and 
fenestrations remained evenly spaced in the choriocapillaris. Lastly, mitochondria 
appeared unchanged, displaying clear outer membranes with organized cristae.
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Figure 2.10 Ultrastructural changes in WT and CFB −/− mice following CE. Electron 
micrographs of the RPE/BrM/choriocapillaris complex (RPE/BrM/CC) obtained from WT and 
CFB −/− mice exposed to 6 months of cigarette smoke (CE) or room air were compared. (A) In 
a WT animal raised in room air, BrM exhibits an organized pentalaminar structure, consisting 
of RPE-BM, RPE basement membrane; ICL, inner collagenous layer; MEL, middle elastic 
layer; OCL, outer collagenous layer; CC-BM, choriocapillaris basement membrane; and the 
choriocapillaris endothelium has fenestrations along the entire membrane. (B) The RPE/BrM/
CC in a WT animal exposed to smoke exhibits pathological changes. BrM is disorganized, 
losing its pentalaminar structure, and large deposits are present within the OCL. Note the 
presence of choriocapillaris fenestrations (arrowheads) overlying BrM of normal thickness, but 
fenestration loss and/or endothelial cell thickening adjacent to OCL deposits (asterisks). (C) 
The RPE/BrM/CC is not affected by the elimination of CFB, but is preserved in CFB −/− mice 
exposed to smoke inhalation (D). Insets highlight the morphological features of mitochondria 
with degraded outer membranes and disorganized cristae in WT mice exposed to smoke and 
normal appearance in the other three samples.
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 EM results were quantified for the criteria listed above (Table 2.2) focusing 
on aspects of energy metabolism in the RPE (mitochondria and BL-infoldings), 
nutrient and waste transport (thickness of BrM) and photoreceptor function 
(photoreceptor OS width and size of cell body). RPE cell morphology was 
drastically altered in WT mice exposed to smoke. Mitochondria were found to be 
significantly larger in C57BL/6J smoke-exposed animals compared to controls 
(P<0.04), and made up a larger percentage of the total RPE cell area (P<0.05). 
Both of these criteria remained unchanged after CE in CFB −/− animals. The total 
number of mitochondria remained unchanged in both genotypes. Interestingly, 
we also observed a treatment-dependent percent volume reduction of the BL-
infoldings under smoking conditions for both genotypes (P<0.02). A robust 
thickening of BrM was observed in WT mice exposed to smoke (P<0.05) that was 
absent in CFB −/− mice. Finally, we determined the average width of the rod 
photoreceptor OS and the area in the ONL occupied by photoreceptor cell 
bodies. WT mice had significantly thinner rod OS following CE (P<0.05), and 
exhibited photoreceptor hypertrophy and/or Müller cell atrophy when compared 
to controls (P<0.02). In comparison, CFB −/− photoreceptor OS width and cell 
body size was unaffected regardless of treatment.
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Table 2.2. Quantification of morphological structures from WT and CFB −/− mice following 
CE. All area and length/width measurements are expressed in µm2 and µm, respectively. MITO, 
mitochondria; BrM, Bruch’s membrane; ICL, inner collagenous layer; BL, basal laminar infoldings; 
OS, outer segment. Data are expressed as mean ±SEM (n=4-6 per group; ✝, P<0.05; ✝✝, 
P<0.01).




MITO Number 31.66±2.17 32.50±2.44 31.25±3.13 33.05±1.67
MITO Area 29.94±1.95 40.21±3.75	  ✝ 33.88±2.08 33.86±1.05
BrM ICL Thickness 0.15±0.01 0.18±0.01 ✝ 0.15±0.02 0.12±0.00
BL % Area 75.28±1.07 67.17±2.02 ✝ 72.04±1.64 63.88±1.14 ✝✝
OS Width 1.61±0.07 1.35±0.08 ✝ 1.53±0.03 1.46±0.08
Müller Cell % Area 27.85±1.42 21.46±1.27 ✝ 22.73±1.25 23.39±1.21
Mitochondrial Relocalization Following CE is Absent in AP Deficient 
Animals
 Organelles in the RPE are distributed throughout the cell in a unique 
fashion: that is, mitochondria are localized along the basal and basolateral 
membranes, whereas melanocytes are localized predominantly along the apical 
surface. Mislocalization of organelles has been recognized as a hallmark of 
damaged RPE cells [175]. After 6 months of CE, melanocyte distribution was 
found to be unaltered in both genotypes (data not shown). The mitochondrial 
distribution profile for WT control mice confirmed that mitochondria are localized 
along the basal (33.2±2.7%) and basolateral (40.9±2.7%) sectors of RPE cells 
(Fig. 2.11A), whereas the central and apical sectors contain only 19.1±1.8% and 
6.7±1.0% of the mitochondrial population, respectively. Following 6 months of 
CE, we noticed an apical shift of the mitochondria from the basal sector to the 
central sector (26.3±4.2%, 27.5±4.2%, respectively; P<0.05) (Fig. 2.11B). The 
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basolateral and apical zones did not differ from the controls. The distribution 
profile for CFB −/− room-air controls exhibited a similar mitochondrial distribution 
pattern as the C57BL/6J mice, with the majority of mitochondria sequestered in 
the basal (38.9±1.4%) and basolateral (40.6±2.8%) sectors (Fig. 2.11C). The 
central and apical zones were also similar, containing 14.0±2.3% and 6.4±0.9% 
of the mitochondrial population, respectively. The apical shift observed in C57BL/
6J animals was absent in the CFB −/− mice (Fig. 2.11D) following 6 months of 
smoke exposure. The percent distribution in smoke-exposed animals between 
basal, central, apical, and basolateral zones did not differ from age-matched 
room-air raised controls.
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Figure 2.11 Mitochondrial localization is altered after CE. Mitochondrial position was 
determined from electron micrographs (depicted in Figure 2.10) by determining their centroid 
coordinates as a percentage of the corresponding RPE length and thickness, respectively. 
Each centroid was subsequently assigned to one of 4 bins (basolateral, basal, central, or 
apical). (A) The normalized positions of mitochondria within RPE of WT animals exposed to 
room air demonstrates that mitochondria are anchored predominantly along the basolateral 
and basal walls of the RPE cells and are more sparse throughout the central and apical 
portion (see text for more detail). (B) Cigarette smoke exposure (CE) affects the mitochondrial 
distribution in WT animals, with mitochondria exhibiting an apical shift from the basal to central 
compartment. (C) Mitochondrial distribution is not affected by genotype, with CFB −/− mice 
raised under control conditions exhibiting a normal distribution profile. (D) Six months of CE 
had no effect on mitochondrial distribution in CFB −/− animals.
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Discussion
 The main results of the current study were as follows: (1) WT mice 
exposed to long-term smoke inhalation exhibited functional (ERG) and behavioral 
(OKR) deficits in retinal function; (2) alterations in gene regulation in pathways 
involved in photoreceptor signal transduction, as well as a RPE cell metabolism, 
complement activation, angiogenesis, and catabolism may underlie these 
observed differences; (3) CE caused morphological changes in RPE-BrM that are 
similar to those observed in AMD such as thickening of BrM, deposit formation in 
BrM, loss of BL-infolding of the RPE and dislocation of mitochondria; (4) these 
changes in RPE-BrM may result in impairment of photoreceptor cell integrity as 
evidenced by retinal thickness changes in OCT and photoreceptor morphometric 
analyses in electron microscopy; (5) CFB −/− animals appear to be protected from 
almost all smoke-induced changes that were observed in WT animals.
 Dry AMD is considered a progressive disease, resulting in the gradual loss 
of vision. The earliest clinical hallmarks observable are either the appearance of 
drusen above a critical size (≥63 µm) and/or pigmentary changes in the center of 
the globe [133]. Drusen are deposits made up of proteinaceous and lipid debris, 
and are located between the RPE and the ICL of BrM. Since alterations due to 
dry AMD and the normal aging processes overlap, it is difficult to assign observed 
alterations to one or the other. Additional changes that occur include the 
progressive thickening of both the inner and outer collagenous layer of BrM, 
including the development of inclusions in the collagenous and elastin layers of 
BrM [176]. In areas of RPE damage, choriocapillaris alterations, including 
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reduction in fenestration or dropout, have been observed [177]. These alterations 
in the choriocapillaris may be the underlying reason for the impaired perfusion 
recognized in AMD [178]. Thickening of BrM, seen when using fluorescein 
angiography, has been postulated to act as a diffusion barrier between the 
choroid and BrM in AMD patients [179], which is supported by the observation of 
age- and lipid-related changes in permeability of BrM for macromolecules [180, 
181]. Loss of photoreceptor function and structure is associated with dry AMD. In 
particular, abnormalities in dark adaptation of both rods and cones [182], with 
raised cone thresholds in the parafoveal region [183], have been observed. Loss 
of function may be due to retinoid deficiency based on the changes in BrM 
permeability. This hypothesis is supported by experiments conducted by Owsley 
et al. [165], demonstrating rod-mediated dark adaptation can be improved by 
high doses of oral retinol. However, dropout of photoreceptors has been reported 
in dry AMD starting in the parafoveal region, affecting both rods and cones [184].
 The only environmental agent unequivocally linked to AMD is cigarette 
smoke [102], and epidemiological studies have linked smoking to the progression 
of AMD [185]. The most likely target for toxicity is the RPE, presumably by 
generating oxidative stress. Although the RPE is constantly exposed to toxic 
oxygen intermediates, it has available effective defenses against oxidative 
damage, including high amounts of anti-oxidants [186]. The RPE anti-oxidative 
capability is reduced with age [187, 188], and exposure to cigarette smoke may 
accelerate this normal age-related decline in RPE cell function.
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 Dry AMD has long been associated with inflammation and the complement 
cascade [138]. However, not until the association of SNPs in the AP inhibitor, 
CFH, with AMD risk, did that idea gain traction [91-93, 135]. While there are other 
SNPs in genes that belong to the complement cascade (reviewed in Hecker and 
Edwards [189]), the strongest link is with CFH. Additional support linking CFH to 
AMD comes from patients with membranoproliferative glomerulonephritis 
(MPGN) type II, a disease associated with CFH mutations, who develop drusen 
which are indistinguishable from those in AMD [190]. Smoke extract has been 
shown to be able to activate the AP in vitro [82] and serum levels of complement 
components are elevated in smokers [191]. In a previous mouse study, using a 
comparable smoke exposure model, components of the complement pathway 
were identified between RPE and choroid in smoke-exposed, but not control 
animals [150]. Those components included the anaphylatoxin C3a, complement 
component C5, the MAC, as well as CFH. Thus, it appears likely that an 
increased activity in the AP, both systemically and locally, may mediate the AMD-
like changes observed in the RPE/choroid and retina in animals exposed to 
constant smoke.
 Here, we examined the effects of long-term CE on retinal structure and 
function in mice. Similar to AMD patients, we noticed a decrease in b-wave 
amplitudes under both scotopic and photopic conditions in WT mice exposed to 
smoke. In particular, under dark-adapted conditions, ERG amplitudes were 
diminished at light intensities sufficient to stimulate both rods and cones 
(mesopic range). In addition, contrast sensitivity under photopic conditions was 
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reduced, while spatial acuity at maximum contrast was unaffected. The results of 
the QRT-PCR analysis allowed us to investigate several possible hypotheses. 
One scenario is that smoke exposure may reduce the amount of pigment 
available to trigger the phototransduction cascade. Gene expression levels for 
rhodopsin were found to be unaltered by smoke exposure whereas mRNA levels 
for UV- and MWL-cone opsin were both reduced approximately 2-fold; correlating 
with the functional results. A second potential reason for the reduction in function 
is that smoking reduces the amount of the rate-limiting enzyme, RPE65, required 
to generate the chromophore, 11-cis retinal. The QRT-PCR data revealed an 
approximately 3-fold decrease in Rpe65 mRNA levels following CE, which if 
translated into a 3-fold reduction in protein level would significantly impact 
chromophore formation [192]. Taken together, these results suggest that both 
cone apoprotein and chromophore production is reduced in smoke-exposed 
animals, leading to the observed decline in visual function in mesopic and 
photopic ranges. Future experiments are required to determine whether a 
reduction in cone opsin gene expression translates into shorter cone OS, or a 
drop-out in cones. However, the decrease in visual function following CE was 
accompanied by a thinning of both the ONL and INL as determined by OCT. 
Interestingly, in clinical studies, the thickness of the ONL has been shown to 
highly correlate with visual acuity in patients diagnosed with dry AMD [193]. Here, 
we cannot conclude that the thinning is due to cell loss; cell counts would need to 
be completed to further support this hypothesis. An alternative interpretation in 
light of the electron microscopy data, showing an apparent Müller cell atrophy 
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(Table 2.2), might be that the cell bodies of the photoreceptors are equal in 
number, but closer together, resulting in a thinner ONL.
 A growing body of literature suggests that dysfunctional mitochondria may 
lie at the core of AMD etiology [34, 35]. Feher et al. [36] have reported age-
related changes in mitochondrial morphology that are accentuated in AMD. Aged 
RPE contain mitochondria that show membrane disorganization, a focal loss of 
cristae, and disruption of their apical-basal alignment. Work by He and Tombran-
Tink [37] showed that cultured RPE cells from aged donor eyes contain large, 
fused mitochondria that generate less ATP than those obtained from young 
donors. Interestingly, exposing mice to smoke replicates many of the changes 
seen in the mitochondria of aged RPE cells. We found that CE leads to 
mitochondria that display a damaged phenotype, with fractured outer membranes 
and disorganized cristae. In addition, mitochondria were found to be significantly 
enlarged (Table 2.2). In support of the balance between mitochondrial fission and 
fusion being tipped towards fusion, Mfn1 was found to be increased ~14-fold, 
whereas the fission protein, Dnm1l, was only increased 3-fold in the RPE of 
smoke-exposed animals. Since larger mitochondria need more mitochondrial 
respiratory proteins, it was logical to find that Ndufb8 and mt-Co1 were both 
upregulated 4-fold. Although mitochondrial respiration has not yet been 
measured in RPE cells obtained from smoke-exposed mice, mitochondrial ATP 
production is expected to be lower. In support of this hypothesis, we observed 
that gene expression for Pfkfb1, the rate-limiting enzyme in glycolysis, was found 
to be significantly increased. An increase in ATP production via glycolysis, an 
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anaerobic redox reaction, is often observed under conditions of limited ATP 
synthesis by oxidative phosphorylation such as oxidative stress (Warburg effect 
[194]). Mitochondria are mobile organelles that tend to sequester in areas of high 
metabolic demand [195]. However, they can also move in response to 
physiological changes, which we observed in the mitochondrial distribution 
analysis. Taken together, we hypothesize that an inability to power the cellular 
machinery used to generate chromophore and shuttle nutrients and waste 
between the RPE and choroid, a consequence of defective mitochondria, might 
contribute to the visual defects that develop in the smoke-exposed animals.
 In addition to these mitochondrial deficiencies in the RPE, we observed a 
thickening of BrM and formation of outer collagenous deposits. These deposits 
were similar to the ones found by Mettu et al., using long-term exposure of mice 
to hydroquinone, an abundant oxidant in cigarette smoke, but differ in location 
from deposits in dry AMD [164]. In addition, alterations in the choriocapillaris 
such as a loss of fenestrations in areas opposing the large BrM deposits were 
observed. These morphological alterations may impede the aforementioned 
transport of nutrients and waste between the RPE and choroid, ultimately leading 
to impairment of photoreceptor cell function and structure. It is unclear as to the 
source of the material accumulating in BrM. However, as all markers of 
autophagy, the catabolic process responsible for removing damaged proteins 
and organelles, were all significantly down-regulated in the RPE from smoke-
exposed animals. The increased amount of undigested material may get 
exocytosed on the basal side of the RPE, resulting in deposit formation. 
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Interestingly, Wang et al. [150] reported a decrease in lysosomal activity in a 
culture model of aged RPE cells, and suggested that “the release of intracellular 
proteins via exosomes by the aged RPE may contribute to the formation of 
drusen.”
 As indicated above, smoke exposure has been shown to be associated 
with an increase in complement activation in human patients [191], an increase in 
the risk for AMD [102], and an increase in complement deposition in the mouse 
eye [150]. Here, we found complement C3d deposition on the basal side of the 
RPE, indicating complement activation. Furthermore, we demonstrated increased 
complement gene expression for C3 and Cfb, a significant decrease in the 
membrane-bound and fluid phase inhibitors (CD55, CD59, and CFH) in the RPE, 
as well as increased expression of AP complement proteins, C3 and C5 in the 
liver. Most importantly, we found that the great majority of the functional and 
structural alterations triggered by CE were absent in mice that lack the AP of 
complement activation. These mice have a functional CP and LP, but lack the 
tick-over process of spontaneous AP activation, as well as the AP amplification 
loop. Our observations in CFB −/− mice can be paralleled by data from patients 
with the CFB protective (R32Q) and CFH risk (Y402H) alleles. The R32Q allele, 
which results in a CFB with less activity [142], is correlated with reduced drusen 
size and total drusen area [143]. Likewise, the Y402H allele, which binds less 
effectively to malondialdehyde epitopes and oxidized phospholipids (generated 
by oxidative stress [125, 196]), is correlated with the size of peripheral drusen 
and increases in reticular pigment [140, 141]. While both the human and our 
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mouse data presented here suggest that increased AP activation is mediating 
structural damage in RPE/BrM, a contribution of altered gene expression and 
hence altered cellular homeostasis generated by R32Q, Y402H, or the lack of 
CFB (Fig. 2.6) cannot be excluded. Complement effector systems are capable of 
inducing inflammation, driving direct cell injury, and bridging the innate and 
adaptive immune system through the interaction of complement opsonins and 
anaphylotoxins. The precise mechanisms of complement-mediated injury herein 
is difficult to determine, and further studies need to be conducted to investigate 
the contributions of upstream and downstream components of the complement 
cascade on smoke-induced pathologies. To date, the presence of C3 activation 
fragments and MAC deposition in CE mice, together with the noted amelioration 
of disease in CE CFB −/− mice supports the hypothesis that AP-mediated 
activation of the complement system plays a role in CE-induced AMD pathology, 
through complement-mediated effector mechanisms. However, a clear and sole 
contribution of the MAC cannot be ascertained, given that complement opsonins 
and anaphylatoxins can promote inflammation, cytokine release, and bridge 
adaptive immune responses that may progress AMD pathology independent of 
direct complement-mediated lysis. Finally, our group has generated a novel 
recombinant form of the AP inhibitory protein, CR2-FH, consisting of the AP-
inhibitory domain of mouse CFH, linked to a CR2 targeting fragment that binds 
complement activation products. CR2-FH has been used successfully to inhibit 
mouse choroidal neovascularization, a process requiring AP activation [81]. It 
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would be of great interest to test this novel therapeutic to determine if smoke-
induced retinal damage is preventable and/or reversible.
 Taken together, there is growing evidence linking oxidative stress and 
smoking, as well as complement activation to the development and progression 
of AMD. Our data provided here show that CE in mice leads to functional and 
morphological defects in the retina, RPE, BrM, and choriocapillaris, also seen in 
patients with dry AMD. Our experiments, utilizing mice that lack the AP of 
complement activation, provide the first direct evidence that complement 
activation is required for these functional and structural alterations to occur, and 








 AMD is one of the leading causes of irreversible blindness among the 
elderly in developed countries and is projected to affect 196 million people by 
2020 [1]. AMD is a progressive, degenerative disease of the retina that results in 
central vision loss caused by the degeneration of photoreceptor cells. This late-
onset maculopathy can be diagnosed in two forms: atrophic, “dry”; or 
neovascular, “wet” [133]. The atrophic form of the disease is marked by the 
formation of yellow, lipoprotein deposits known as drusen (≥63 µm in size) in the 
subretinal space between BrM and the RPE. The neovascular form is 
characterized by the proliferation of choroidal blood vessels through BrM into the 
subretinal space. These fragile vessels leak blood and proteins into the 
subretinal or sub-RPE space [134], leading to retinal detachment followed by 
photoreceptor cell death. Patients can develop either form of the disease; 
however, the atrophic form is most common making up 90 percent of all cases 
[2].
 AMD is a multiplex disease that is influenced by genetic and 
environmental factors. Many of the main genetic risk factors are polymorphisms 
occurring in complement genes, a system whose role spans clearance of 
pathogens from an organism to mediating the induction and expansion of 
inflammatory injury. These genes include the AP inhibitor CFH, AP activator CFB, 
complement component C2, and terminal pathway component C3. Perhaps the 
most well-known of these is the Y402H  SNP in the gene encoding CFH. Risk 
variants of the Y402H SNP have been associated with increased levels of 
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granulocyte macrophage colony-stimulating factor in the vitreous and an 
accumulation of choroidal macrophages, suggesting that a dysregulation of the 
proinflammatory cytokines locally in the eye may underlie disease pathology 
[197]. Increased levels of inflammation may be caused by poor binding of the 
402H variants of factor H-like protein and CFH to BrM due to an impaired ability 
to bind heparan sulphate [198, 199]. Furthermore, the effect of ranibizumab, a 
common anti-angiogenic used to treat AMD, has been shown to be more or less 
effective based on the Y402H allele patients express [200]. 
 Cigarette smoke is the most significant environmental factor contributing 
to AMD with an estimated risk increase of 2- to 4-fold [201]. Smoking promotes 
the progression of AMD from the atrophic to neovascular form [56], which may 
occur up to 10 years earlier in smokers compared to non-smokers [53]. However, 
cessation has been shown to decrease the risk of developing AMD and the 
progression to CNV [148]. The exact mechanisms responsible for smokers’ 
susceptibility to AMD is unknown, due in part to the massive number of 
constituents in cigarette smoke, and there are likely a large number of 
contributing factors involved. Both cigarette smoke and hydroquinone (HQ), a 
component of cigarette smoke, induces oxidative damage and apoptosis in 
human RPE cells [151]. HQ also downregulates pro-inflammatory monocyte 
chemoattractant protein-1 and upregulates VEGF in RPE cells, suggesting that 
incomplete clearance of pro-inflammatory debris coupled with increased 
angiogenesis may promote drusen formation and progression to CNV in AMD 
patients [71]. Finally, smoke extract has been shown to directly activate C3 [82] 
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and trigger complement-dependent endoplasmic reticulum stress and lipid 
deposition in ARPE-19 cells [126], providing a clear link between smoking and 
complement activation.
 Previous studies have shown that mice exposed to second hand cigarette 
smoke over a long period of time exhibit activation of the terminal pathway of the 
complement system in the RPE and choroid, concomitant with damage to the 
RPE and photoreceptors [66, 70, 150-152]. We followed up on these findings by 
investigating the effects of long-term CE in WT mice or mice lacking a functional 
AP (CFB KO). CE in WT mice resulted in functional (decrease in rod and cone 
ERG amplitudes), behavioral (decrease in cone-dependent contrast sensitivity), 
molecular (altered gene expression in the RPE and photoreceptors), and 
morphological (increase in mitochondrial size in the RPE, thickening of BrM) 
impairment, while CFB KO mice were protected from developing any CE-
mediated alterations [202]. The purpose of this paper is to build on these findings 
by determining whether the detrimental effects caused by chronic CE are 
reversible following treatment with a novel AP inhibitor (CR2-FH). We 
hypothesized that WT mice would recover from smoke-induced deficits based on 
previous studies from our lab that have demonstrated efficacy for CR2-FH in 
ameliorating laser-induced choroidal neovascularization, reducing RPE injury and 
angiogenesis in mouse models of AMD [81, 203, 204], as well as preventing 





 C57BL/6 mice were purchased (Jackson laboratory, Bar Harbor, ME) 
[153], and we previously confirmed that these mice were negative for the RD8 
locus [202]. Animals were housed under a 12:12 h, light:dark cycle with access to 
food and water ad libitum. 
 For tail-vein injections, the vein was vasodilated by heat, a 25-gauge 
needle was inserted, and a 100 µL volume was injected (250 µg CR2-fH in PBS 
or PBS only). Dosing and treatment schedules are outlined in the Results 
section. All experiments were approved by the Medical University of South 
Carolina Institutional Animal Care and Use Committee and performed in 
accordance with the Association for Research in Vision and Ophthalmology 
statement for the use of animals in ophthalmic and vision research.
Exposure to Cigarette Smoke
 Eight-week-old C57BL/6J male mice were divided into three groups (n = 6 
per group). The control group was kept in a filtered air environment, and the two 
experimental groups were subjected to cigarette smoke. CE was carried out (5 
hours per day, 5 days per week) by burning 3R4F reference cigarettes (University 
of Kentucky, Louisville, Kentucky, USA) using a smoking machine (Model TE-10; 
Teague Enterprises) for 6 months. The average concentration of total suspended 
particulates was 130 mg/m3 and was monitored twice daily.
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Plasmid Construction, Expression, and Purification of CR2-FH
 Expression plasmids for the generation of CR2-FH were prepared as 
previously described [81]. Briefly, the sequence encoding the four N-terminal 
SCRs of mouse CR2 (residues 1-257 of mature protein; RefSeq NM 00758) was 
linked to the sequence encoding the 5 N-terminal SCRs of mouse CFH (residues 
1-303 of mature protein; RefSeq NM 009888) with a (G4S)2 linker. The expression 
plasmid was the previously described PBM vector with a C5 signal peptide 
sequence [205]. Final plasmid constructs were transfected into Chinese hamster 
ovary cells with transfection reagent (FuGene HD; Roche Applied Science, 
Indianapolis, IN) according to the manufacturer instructions, and protein 
expression was quantified by ELISA and dot blot analysis. For protein 
purification,Chinese hamster ovary cells expressing CR2-FH were cultured in 
flasks (375 cm2), and culture supernatant was centrifuged at 2000g for 20 
minutes, then filtered through a 0.22-µm filter. CR2-FH was purified from the 
filtered supernatant by anti–mouse CR2 (mAb 7G6) affinity chromatography, as 
previously described [205]. Detailed in vitro characterization of the fusion protein 
demonstrating AP specific activity has been reported [206]. 
Optokinetic Response Test
 Visual acuity and contrast sensitivity of mice were measured by observing 
their optomotor responses to moving sine-wave gratings (OptoMotry) as 
previously described [155]. Mice reflexively respond to rotating vertical gratings 
by moving their head in the direction of grating rotation. To observe these 
movements, mice were placed individually on the central elevated pedestal 
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surrounded by a square array of computer monitors that display stimulus 
gratings. Mice were monitored via an overhead closed-circuit TV camera that 
allowed the observer to view only the central platform and not the rotating 
grating. Mice were allowed to adjust to the chamber for 2 min with the monitors 
displaying a 50% gray uniform field prior to testing, and monitors returned to a 
homogenous gray between trials. All tests were conducted under photopic 
conditions with a mean luminance of 52 cd m−2. Visual acuity was measured by 
finding the spatial frequency threshold of each animal at a constant speed (12 
deg/s) and contrast (100%) with a staircase procedure that systematically 
increased the spatial frequency of the grating until the animal no longer exhibited 
detectable responses. Contrast sensitivity was determined by taking the 
reciprocal of the contrast threshold at a fixed spatial frequency (0.131 cyc/deg) 
and speed (12 deg/s). It has previously been determined that this spatial 
frequency falls within the range of maximal contrast sensitivity for 9-month-old 
C57BL/6J mice (data not shown). Contrast of the pattern was decreased 
systematically in a staircase manner until the animal stopped responding.
Quantitative RT-PCR
 RPE/choroid and retina fractions were isolated from control and smoke-
exposed animals and stored at −80°C until they were used. QRT-PCR analyses 
were performed as previously described in detail [156]. In short, real-time PCR 
analyses were performed in triplicate in a GeneAmp® 5700 Sequence Detection 
System (Applied Biosystems) using standard cycling conditions. Quantitative 
values were obtained by the cycle number, normalizing genes of interest to β-
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actin, and determining fold difference between room air and CE within 
genotypes. Fold difference values were compared using Z-test analyses, 
accepting a significance of P<0.05. See Table 2.1 for a full list of primers used for 
QRT-PCR.
Tissue Preparation
 The eyes were enucleated, and a slit was cut into the cornea to allow for 
rapid influx of fixative. Eyes were fixed overnight in 2.5% glutaraldehyde, 1% 
formaldehyde, 3% sucrose, and 1 mM MgSO4 in 0.1 M cacodylate buffer, pH 7.4. 
The eyes were then dissected and small central portions were osmicated for 60 
minutes in 0.5% OsO4 in 0.1 M cacodylate buffer, processed in maleate buffer for 
en bloc staining with uranyl acetate, dehydrated in graded ethanols, and 
processed for resin embedding as in [157]. Serial sections were cut at 90 nm on 
a Leica Ultramicrotome onto carbon-coated Formvar® films supported by nickel 
slot-grids.
Ultrastructural Analysis
 EMs were captured using a JEOL JEM 1400 transmission electron 
microscope using SerialEM software to automate image capture overnight with 
1200–1500 images captured per section, yielding datasets that were then 
processed with the NCR Toolset [158, 159] to generate image mosaics with 
corrections for image aberrations induced by electron microscopy.
 Electron microscopy images were evaluated using Adobe® Photoshop® 
and ImageJ software. For each animal, two RPE cells were outlined using the 
apical processes and the basal lamina (thickness) as well as the basolateral 
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walls (length) as borders. A masking-layer for all mitochondria present within an 
RPE cell was created to calculate average mitochondrial number and size. BrM 
thickness was determined by analyzing ~200 µm sections of BrM. A masking 
layer was created over segments of BrM, using choroidal intercapillary pillars and 
the basement membrane of the RPE and CC as boundaries. The area of the 
masking layer was divided by the length of each segment to determine an 
average BrM thickness for each segment. We then calculated a weighted 
thickness average based on the percentage length of each segment versus the 
entire ~200 µm section being analyzed. Finally, we determined average BrM 
thickness by summing weighted averages for each section. The number of OCL 
deposits was calculated along a ~200 µm section of BrM. An ‘OCL deposit’ was 
defined as the presence of any discrete focal nodule of homogenous material of 
intermediate electron density between the OCL of BrM and the basement 
membrane of the CC. ONL thickness was determined by averaging 
measurements taken at five arbitrary points along a ~200 µm section of retinal 
tissue, using the outer plexiform layer (upper) and outer limiting membrane 
(lower) as boundaries. Müller cell percent area was determined by subtracting 
the area occupied by the rod/cone somas in a ~600 µm2 area of the ONL and 
dividing by the total area analyzed; using the same masking technique as 
described from BrM thickness analysis. Photoreceptor cell counts were 
determined by counting the number of cell bodies present within a ~600 µm2 area 
of the ONL.
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 Mitochondrial distribution profiles were generated by performing a percent 
normalization on the coordinates of centroids for all mitochondria with respect to 
the length/width of the RPE cell they were imaged from. After plotting the data, 
we assigned each mitochondrion to one of 4 bins as follows: basolateral (x-value 
<0.20 or x-value >0.80), basal (0.20≤ x-value ≤0.80 and y-value <0.33), central 
(0.20≤ x-value ≤0.80 and 0.33≤ y-value <0.66), and apical (0.20≤ x-value ≤0.80 
and 0.66≤ y-value <1). Significance values were based on the percentage of 
mitochondria that fall into each bin.
Statistics
 For data consisting of multiple groups, repeated measures ANOVA 
followed by the Fisher post hoc test (P<0.05) was used; single comparisons were 
analyzed using the Student t-test assuming equal variance (P<0.05; Statview; 
SAS Institute, Inc.). Fold changes in QRT-PCR experiments were analyzed using 
a Z-test (P<0.05).
Results
Effect of CR2-FH Treatment on Smoke-Induced Impairment of Visual 
Function
 There is ample evidence that morphological and cellular alterations lead to 
vision loss or impairment in dry AMD. Dry AMD in patients is associated with 
drusen formation and a thickening of BrM that can eventually lead to 
photoreceptor degeneration [162, 163, 207]. Amyloid-beta, a component of 
drusen, reduces mitochondrial redox potential and increases the production of 
reactive oxygen species in RPE cells [208], resulting in a metabolic imbalance 
and contributing to geographic atrophy. Structural changes to BrM can lead to 
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impaired exchange of waste and nutrients between the RPE and choroid [164] as 
well as a reduction in the generation and delivery of 11-cis-retinal, a vitamin-A-
based chromophore essential for proper visual function, to photoreceptor outer 
segments [165]. These AMD-associated pathologies manifest as reductions in 
visual function, which can be measured by changes in visual acuity and contrast 
sensitivity. These pathological alterations are associated with increased 
deposition of activation products of the complement system in drusen and BrM 
[138, 209] and reduced expression levels and altered distribution of complement 
inhibitors [78, 79, 210]. There seems to be a consensus that complement 
activation is involved in promoting drusen formation and BrM thickening; 
however, it is unclear whether continued complement activation is required to 
maintain these structures. Or in other words, can complement inhibitors be used 
to restore ocular health?
 To mimic complement-dependent RPE-BrM changes and visual function 
loss seen in dry AMD, we used a smoke inhalation model in mice (reviewed in 
[211]). After 6 months of CE, we measured visual function in animals via OKR 
testing before they were returned to room air and randomly divided into two 
experimental groups, PBS and CR2-FH. The inhibitor, CR2-FH, has both a 
targeting domain (SCRs 1-4 of CR2) and the complement inhibitory domain of 
CFH. CR2 acts as a targeting moiety, since it binds to cell-bound cleavage 
fragments of C3 present at sites of complement activation [212]. Animals were 
treated once a week (250 µg/animal in 100 µL of PBS) for three months. We 
performed OKR tests to determine the effects of CR2-FH on visual function. 
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Spatial frequency (Fig. 3.1A) and contrast sensitivity (Fig. 3.1B) were measured 
under photopic light conditions. Both measures of visual function are influenced 
by inner and outer retina function and correlate with photoreceptor cell function 
[213]. A reduction in spatial frequency threshold (spatial acuity) can be observed 
in rodents following RPE [168] or photoreceptor cell loss [169], and contrast 
sensitivity correlates with photoreceptor cell viability as observed in retinal 
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Figure 3.1 Post treatment with CR2-FH reverses smoke-induced impairment of 
contrast sensitivity. Optomotor responses were analyzed in WT mice after 6 months 
of cigarette smoke exposure (CE) or room air followed by 3 months of treatment with 
nothing, PBS, or CR2-FH. (A) Visual acuity was measured by identifying the spatial 
frequency threshold at a constant speed (12 deg/sec) and contrast (100%). Spatial 
frequency thresholds were not affected by treatment. (B) Contrast sensitivity was 
measured by taking the reciprocal of the contrast threshold at a fixed spatial frequency 
(0.131 cyc/deg) and speed (12 deg/sec). We previously determined that this spatial 
frequency falls within the range of maximal contrast sensitivity for 9-month-old WT 
mice (data not shown). WT mice after CE showed a significant reduction in contrast 
sensitivity compared to controls. However, smoke-exposed mice treated with CR2-FH 
showed a contrast sensitivity that is similar to room air controls and significantly higher 
than PBS-treated mice following CE. Data are expressed as mean ±SEM (n = 4-6 per 
condition; *, P<0.01).
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degenerate mice (rd10) [170] and the Royal College of Surgeons rat [171]. 
 Spatial acuity in WT mice after CE (pre-treatment) did not differ from that 
of control animals exposed to room air (Smoke+PBS 0.31±0.01 versus 
0.31±0.01; P=0.65, Smoke+CR2-FH 0.32±0.01; P=0.80) Spatial acuity in CE 
mice followed by PBS treatment did not differ from age-matched room air 
controls (0.30±0.01 cyc/deg versus 0.31±0.02 cyc/deg; P=0.53). Likewise, 
treatment of CE mice for 3 months with CR2-FH had no effect on spatial acuity 
when compared to vehicle controls (0.33±0.02 cyc/deg; P=0.55). There were also 
no significant pre-post treatment differences in spatial acuity for any group. 
Previously, we have shown that contrast sensitivity is significantly reduced by 
cigarette smoke exposure [202]. Here, we confirmed these findings showing that 
WT mice following CE (pre-treatment) exhibit a significant decrease in contrast 
sensitivity compared to room air controls (Smoke+PBS 4.57±0.97 versus 
10.14±0.41; P<0.01, Smoke+CR2-FH 5.78±0.52; P<0.01). Furthermore, we 
found that CE mice treated with PBS for 3 months still exhibit a robust decrease 
in contrast sensitivity (4.89±1.14) compared to room air controls (9.97±0.53; 
P<0.01). Importantly, contrast sensitivity threshold in CE mice treated with CR2-
FH recovered to levels similar to those of non-smoked, age-matched controls 
(9.14±0.39; P=0.29), levels which are dramatically higher than those of smoked-
exposed, vehicle-treated animals (P<0.05). There were no significant pre-post 
treatment differences for room air controls (P=0.80) or CE mice treated with PBS 
(P=0.84), however CE mice treated with CR2-FH showed a significant increase 
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in contrast sensitivity following treatment (P<0.01), suggesting that CR2-FH was 
able to reverse smoke-induced deficits in contrast sensitivity.
Effect of CR2-FH Treatment on Smoke-Induced Changes in Gene 
Expression
 To further understand how CR2-FH treatment following CE may be 
affecting visual function, QRT-PCR was performed for a wide range of genes that 
fall into one of six categories: photoreceptor cell function, complement activation, 
control of angiogenesis, oxidative stress, autophagy, and mitochondrial function. 
With the exception of rod and cone opsin gene levels, which were determined in 
retina samples, all other genes reflected changes in the RPE/choroid fraction. 
The fold-difference between room-air and smoke-exposed animals following 
treatment with PBS or CR2-FH are plotted (Fig. 3.2).
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 Changes in gene expression following smoke-exposure for genes 
belonging to all six aforementioned categories have been previously shown 
[202]. Here, we asked whether these genes play a role in the recovery of visual 
function in CE mice treated with CR2-FH. Since CR2-FH treatment increased 
contrast sensitivity after CE, we examined levels of genes encoding for the 
apoproteins of the photopigments as well as the rate-limiting enzyme for the 
Figure 3.2 Gene expression changes in ocular tissues following treatment with CR2-FH 
in smoke-exposed mice. Analysis of marker gene expression in smoke-exposed mice 
following treatment with PBS or CR2-FH, using quantitative RT-PCR on cDNA generated from 
RPE/choroid/sclera fraction and retina. Quantitative values were obtained by cycle number 
(Ct value), determining the difference between the mean experimental and control (Actb) ΔCt 
values for PBS- and CR2-FH-treated mice following cigarette smoke exposure (CE) versus 
room-air-exposed mice (fold difference). Candidates were examined from a number of 
categories including photoreceptor cell function (Rho, Opn1sw, Opn1mw, Rpe65), 
complement activation (C3, Cfb, Cfd, Cfh, Cd55, Cd59a), control of angiogenesis (Vegfa, 
Serpinf1), oxidative stress (Hif1a, Cp), autophagy (Lyz1, Lamp2, Klc3), and mitochondrial 
function (Mfn1, mt-Co1, Dnm1l, Ndufb8, Pfkfb1, Hmox1). Significant changes were identified 
in several categories for CR2-FH-treated mice, suggesting decreased complement activation 
and enhanced energy production. Statistics represent comparisons between PBS- and CR2-
FH animals following CE. Data are expressed as mean ±SEM (n = 3 per condition; *, P<0.01; 
** P<0.001; ***, P<0.0001).
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production of the chromophore required for all pigments, RPE65. However, no 
differences were observed in mRNA levels of genes involved in photoreceptor 
cell function. CE has been shown to increase complement activation in the 
mouse RPE [150]. Here, we find that mice treated with PBS for 3 months 
following CE still exhibit changes in gene expression in the RPE/choroid for 
complement genes, including increases in essential components of the 
alternative and terminal pathway, CFB, CFD, and C3; and decreases in 
complement inhibitors, CD55 and CD59. Treatment with CR2-FH decreased the 
expression of CFB and CFD by 30- and 60-fold, respectively. Significant 
decreases in CFH, CD55, and CD59 expression likely represent compensatory 
mechanisms caused by the introduction of an exogenous AP inhibitor. Although 
CR2-FH treatment was associated with a significant decrease in the expression 
of anti-angiogenic factor, PEDF (Serpinf1), compared to PBS-treated animals, 
these levels were not different from room-air controls. Genes associated with 
oxidative stress and autophagy were not altered in a significant manner, with the 
exception of lysozyme 1 (Lyz1). A five-fold decrease in Lyz1 mRNA expression 
was observed in CR2-FH-treated mice compared to PBS-treated animals. 
Lysozyme has been shown to inhibit the haemolytic activity of serum complement 
in a dose-dependent manner [214]. Therefore, this decrease in Lyz1 may be 
reflect a compensatory downregulation related to enhanced complement 
inhibition in CR2-FH-treated animals. An increase in mitochondrial number and 
decline in mitochondrial function has been reported in response to tobacco 
smoke [173]. In support of reducing mitochondrial stress and biogenesis, we 
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found that treatment with CR2-FH resulted in a significant decrease in 
mitochondrial genes in RPE/choroid affecting mitochondrial fission and fusion 
(mitofusin 1, Mfn1; dynamin 1-like, Dnm1l) and an increase in protective 
response gene heme oxygenase (decycling) 1 (Hmox1) when compared to PBS-
treated mice. However, 6-phosphofructo-2-kinase/fructose-2,6-biphosphate1 
(Pfkfb1), the rate limiting enzyme in glycolysis, was found to be upregulated in 
CR2-FH- versus PBS-treated animals, suggesting that ATP production via 
glycolysis is still necessary to meet energy demands.
Post Treatment with CR2-FH Abolishes Morphological Distubances in RPE-
BrM Caused by CE
 Loss in contrast sensitivity following smoke-exposure has previously been 
shown to be associated with specific morphological alterations in RPE, BrM, and 
Müller cells [202]. Here, we asked whether these same features play a role in the 
recovery of visual function in CE mice treated with CR2-FH. We analyzed EMs 
obtained from CR2-FH and PBS cohorts based on the following criteria: BrM 
thickness, mitochondrial morphology, and Müller cell area. Representative EMs 
for WT non-smoked controls (Fig. 3.3A), PBS-treated after CE (Fig. 3.3B), and 
CR2-FH-treated after CE (Fig. 3.3C) were depicted. BrM is a pentalaminar 
structure consisting of the basement membrane of the RPE, the inner 
collagenous zone, the middle elastic layer, the outer collagenous zone, and the 
basement membrane of the choriocapillaris. BrM is thicker in CE mice compared 
to non-smoked controls. The pentalaminar structure of BrM was disrupted as 
evidenced by an inconsistent MEL. Areas of BrM disorganization were especially 
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prevalent near large deposits located in the outer collagenous layer (asterisks) 
that are absent in controls. These deposits were associated with lower 
fenestration density (arrows) in the choriocapillaris, which are responsible for 
transferring nutrients and waste across BrM between the choroid and RPE. In 
contrast, non-smoked controls maintained a high fenestration count along the 
choriocapillaris with little to no outer collagenous deposits. Mitochondria (insets) 
were significantly altered in CE animals, characterized by poorly defined outer 
membranes and disorganized cristae. Room air controls displayed healthy 
mitochondria with clearly defined outer membranes and organized cristae. These 
results were consistent with previous findings from our lab obtained from animals 
examined immediately following the completion of the 6 month CE period [202]. 
However, treatment with CR2-FH following CE reversed all smoke-induced 
ultrastructural deficits. BrM appeared intact, exhibiting the full pentalaminar 
structure, without any apparent thickening. Few deposits were found in BrM and 
fenestrations were evenly distributed along the choriocapillaris. Likewise, the 
mitochondrial phenotype also appeared to be healthy, as evidenced by a clear 
outer membrane and organized cristae.
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 EM results were quantified for the aforementioned criteria (Table 3.1) 
focusing on morphological correlates of energy metabolism in the RPE 
(mitochondria), nutrient and waste transport (BrM thickness and outer 
collagenous deposit count), and photoreceptor function (ONL thickness and 
photoreceptor cell count). Mitochondria were found to be significantly larger in 
CE mice compared to non-smoked controls (P<0.05) and made up a larger 
percentage of total RPE cell area (P<0.05). Mitochondrial morphology completely 
recovered during the 3 month period when treated with CR2-FH. The total 
number of mitochondria remained unchanged between all three groups. We 
observed a thickening of BrM in CE mice compared to room air controls, and BrM 
Figure 3.3 CR2-FH rescues ultrastructural changes in WT mice following CE. Electron 
micrographs of the RPE/BrM/choriocapillaris complex (RPE/BrM/CC) obtained from WT mice 
after 6 months of cigarette smoke exposure (CE) or room air followed by 3 months of treatment 
with nothing, PBS, or CR2-FH were compared. (A) In a WT animal raised in room air, BrM 
exhibits an organized pentalaminar structure consisting of RPE basement membrane, inner 
collagenous layer, middle elastic layer, outer collagenous layer (OCL), and choriocapillaris 
basement membrane. The choriocapillaris endothelium has fenestrations (arrowheads) along 
the entire membrane. (B) The RPE/BrM/CC in a WT animal following CE exhibits pathological 
changes. BrM is disorganized, no longer showing a pentalaminar structure and large deposits 
(asterisks) are present in the OCL. Notably, there is significant fenestration loss and/or 
endothelial cell thickening adjacent to OCL deposits. (C) The RPE/BrM/CC is unaffected in WT 
mice treated with CR2-FH following CE. Insets highlight the morphological features of 
mitochondria with degraded outer membranes and disorganized cristae in WT mice exposed to 
smoke (B), but normal appearance in room air controls (A) and WT mice treated with CR2-FH 
following CE (C). 
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thickness was restored when treated with CR2-FH; however, this did not reach 
statistical significance. CE triggers the formation of outer collagenous deposits in 
BrM [202], which are maintained in CE mice treated with vehicle (P<0.01), but 
removed in those treated with CR2-FH. Finally, we measured the thickness of the 
ONL, the number of photoreceptor cell bodies in the ONL, and the area of the 
ONL occupied by Müller cells. Smoke-exposed WT mice had a significantly 
thinner ONL (P<0.05), which is due to Müller cell hypertrophy (P<0.01) rather 
than loss of photoreceptors, as the number of nuclei in the ONL did not change 
with smoking. In contrast, treatment with CR2-FH in animals following CE 
restored the thickness of the ONL to normal levels (P<0.05); however, Müller cell 
hypertrophy was still present (P<0.01). The number of photoreceptor cell bodies 
in the ONL remained unchanged between all groups.
Table 3.1. Quantification of morphological structures from mice treated with CR2-FH 
following CE. All area and thickness measurements are expressed in µm2 and µm, respectively. 
MITO measurements refer to the number, area, and percentage of mitochondrial area occupied 
per RPE cell. OCL Deposit Count reflects the number of deposits per mm. Müller Cell % Area 
refers to the percentage of a 600 µm2 area of the ONL occupied by Müller cells. Photoreceptor 
Cell Count reflects the number of cell bodies present in a 600 µm2 area of the ONL. MITO, 
mitochondria; BrM, Bruch’s membrane; OCL, outer collagenous layer; ONL outer nuclear layer. 
Data are expressed as mean ±SEM (n = 3-6 per group; ✝, P<0.05; ✝✝, P<0.01).
Criteria NS Control Smoke+PBS Smoke+CR2-FH
MITO Number 26.92±1.23 30.00±1.53 30.25±1.64
MITO Area 42.68±2.27 54.62±2.48 ✝ 45.01±1.21
MITO % Area 4.71±0.70 8.30±0.65 ✝ 6.29±0.22
BrM Thickness 0.62±0.03 0.80±0.13 0.61±0.05
OCL Deposit Count 7.84±2.26 38.87±7.05 ✝✝ 4.08±1.42
ONL Thickness 44.77±1.31 36.86±2.79 ✝ 44.65±0.87
Photoreceptor Cell Count 38.60±0.93 39.00±1.16 38.00±0.95
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Criteria NS Control Smoke+PBS Smoke+CR2-FH
Müller Cell % Area 28.87±1.37 18.33±1.41 ✝✝ 21.90±1.67 ✝✝
 Mitochondria in the RPE are distributed throughout the cell following 
particular localization patterns. Typically, they align along the basal and 
basolateral membranes under normal conditions. We have previously shown that 
the mitochondrial distribution profile is disrupted following cigarette smoke 
exposure [202]. Notably, there is an apical shift from the basal to central sector in 
WT mice following CE. Here, we found that there were no significant differences 
between groups in any of the four localization bins analyzed (Fig. 3.4). 
Spontaneous restoration of mitochondrial relocalization during the 3 month 
period following smoke exposure may be the reason we did not observe an 
apical shift in CE mice. 
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Discussion
 Previously, we have shown that long-term cigarette smoke inhalation leads 
to ocular pathology that is dependent on complement activation and requires the 
AP [202]. These changes included deposit formation in BrM, mitochondrial 
swelling and/or fusion in the RPE, a thinning of the ONL, and Müller cell 
hypotrophy, which correlated with a reduction in contrast sensitivity as assessed 
by OKR. Here, we showed that these structural and functional changes do not 
Figure 3.4 Mitochondrial localization is unchanged in CE mice after treatment. 
Mitochondrial position was determined from electron micrographs (depicted in Figure 3.3) by 
determining their centroid coordinates as a percentage of the corresponding RPE length and 
thickness, respectively. Each centroid was subsequently assigned to one of 4 bins 
(basolateral, basal, central, or apical). The normalized positions of mitochondria within RPE of 
WT animals exposed to room air demonstrates that mitochondria are anchored predominantly 
along the basolateral and basal walls of the RPE cells and are more sparse throughout the 
central and apical portion (see text for more detail). Three months of treatment with PBS or 
CR2-FH following cigarette exposure (CE) had no effect on mitochondrial distribution.
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reverse upon cessation of smoking. Importantly, we showed that mice exposed to 
6 months of cigarette smoke inhalation followed by 3 months of room air still 
exhibited behavioral (OKR) deficits in retinal function; morphological changes in 
RPE-BrM including deposit formation in BrM and mitochondrial swelling and/or 
fusion; and changes in ONL thickness and Müller cell size. In contrast, mice that 
were supplemented with the AP inhibitor CR2-FH during the 3 months of room air 
showed a reversal or attenuation of all smoke-induced morphological changes 
and a complete recovery of visual function.
 Here, we confirmed and extended our previous data on retinal structure 
and function in mice following long-term smoke exposure. In particular, we asked 
whether structural and functional changes triggered by 6 months of CE are 
reversible upon cessation of smoking. Previously, we showed that while spatial 
acuity is retained in mice after 6 months of CE, contrast sensitivity is reduced by 
~60%. Allowing mice to recover in room air only marginally affected contrast 
sensitivity, as the threshold after 3 months was still suppressed by ~50%. Spatial 
acuity, as previously shown, remained unchanged between groups. Similarly, the 
thinning of the ONL observed after 6 months of smoke is retained after 3 months 
of recovery, as is Müller cell atrophy, the presence of large numbers of OCL 
deposits in BrM, and the increase in mitochondrial area. Interestingly, overall BrM 
thickness after 3 months of room air was still increased in CE mice by ~30%; 
however, this difference was no longer significant based on the large variability in 
CE mice compared to controls. Finally, the percent volume reduction of BL-
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infoldings previously observed after 6 months of smoke, was no longer apparent 
following recovery in 3 months of room air (data not shown).
 Contrast sensitivity loss, particularly in the short wavelength channel, is 
associated with early AMD [215]. Delayed rod-mediated dark adaptation rather 
than visual acuity, low luminance acuity, and spatial contrast sensitivity can be 
used as a tool to detect early AMD [216], suggesting that eyes with normal cell 
counts, but thickened BrM and drusen formation, exhibit vision changes due to 
the metabolic health of the cells rather than cell loss. On the other hand, 
sustained visual acuity loss in AMD is most commonly associated with foveal 
scarring, pigmentary abnormalities, and foveal GA [217], which are all common in 
dry AMD. Müller cell hypotrophy has not yet been reported in AMD; however, 
Müller cell hypotrophy, concomitant with increased GFAP expression, has been 
found in stressed explanted neonatal rat retina [218]. These stressed Müller cells  
might increase expression of cytokines and chemokines that contribute to the 
inflammatory state of the retina, contributing to photoreceptor cell loss (e.g. 
[219]). The formation of deposits in the OCL of BrM in CE mice are different in 
localization from pathological structures in AMD. Drusen are found between BrM 
and the RPE, reticular pseudodrusen are located internal to the RPE, BLamDs 
are found between the RPE basement and plasma membranes, BLinDs are 
found between the RPE basement membrane and the ICL of BrM [220]. 
Nevertheless, since the deposits in mice are positive for complement activation 
products [202], they appear worth investigating in the context of complement 
dependent ocular deposit formation. Previous reports have shown that RPE from 
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aged subjects or those with advanced dry AMD contain progressively more 
fragmented mitochondria that generate less ATP [37] and show membrane 
disorganization and focal loss of cristae. It is important to note that healthy 
mitochondria undergo constant fission and fusion to maintain a healthy 
mitochondrial network. However, under stress conditions, mitochondria will 
undergo hyperfusion, particularly during periods of starvation [221], followed by 
rapid and extensive fission early in apoptosis [222]. 
 Cigarette smoking is the leading environmental insult associated with AMD 
[223]. The number of pack years of cigarette smokers has been directly linked to 
the risk of developing geographic atrophy and CNV [148], two hallmark features 
of atrophic and neovascular AMD respectively. Experimental evidence exists, 
demonstrating how smoking may contribute to disease. For example, in RPE 
cells, one of the main targets in atrophic AMD, short term cigarette smoke 
exposure results in an increase in oxidative and endoplasmic reticulum stress, as 
well as complement activation via the AP, which leads to lipid accumulation after 
long term smoke exposure [224]. Likewise, the choroid appears to be a target of 
smoking, as chronic cigarette smokers with atrophic AMD have a thinner choroid 
compared to nonsmokers [225]. A less effective choroidal network along with a 
thickening of BrM and drusen formation can result in decreased delivery and 
clearance of nutrients/waste to and from the RPE. Finally, evidence suggests that 
dysregulation of the VEGF/PEDF ratio may be implicated in the pathogenesis of 
CNV in AMD [226]. Interestingly, nicotine, a primary constituent of cigarette 
smoke, has been shown to increase the VEGF-to-PEDF ratio in the RPE through 
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nicotinic acetylcholine receptor-mediated signaling pathways [227], thereby 
promoting angiogenesis. 
 A link between smoking and complement activation in disease has long 
been established, including emphysema [228], cardiovascular disease [229], and 
age-related macular degeneration [223]. Likewise, inflammation and the 
complement cascade have long been associated with dry AMD [138]. However, 
this association was not solidified until SNPs in the AP inhibitor, CFH were linked 
with AMD risk [91-93, 135]. Smoking is the single most prevalent, modifiable risk 
factor for AMD [148] and increases the risk of developing AMD in CFH risk factor 
subjects (402H) in an additive fashion [91-93]. Since smoking increases the 
plasma concentration of complement components [230], and smoke extract 
directly activates C3 [82], it is reasonable to assume that smoking and 
complement activation contribute in an additive fashion to AMD pathology.
 In patients, the question of whether smoke-induced pathology is reversible 
has not yet been addressed. However, Neuner and colleages have posed a 
similar question in the Muenster Aging and Retina Study [231]. The group 
followed aged smokers and non-smokers without AMD over a median of 30.9 
months and reported their adjusted risk ratios for incident AMD. Of the 9.6% of 
subjects that progressed to AMD, the adjusted risk ratio in current versus never 
smokers was 3.25 (95% confidence interval [1.50–7.06]), but was still 
significantly elevated by 1.28 [0.70–2.33] in former smokers versus never 
smokers.
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 As a second question, we asked whether continued complement activation 
was required to maintain the structural and functional deficits observed in smoke-
exposed mice, or whether reversal of damage could be observed upon 
complement inhibition. Our group has generated a novel recombinant form of the 
AP inhibitory protein, CR2-FH, consisting of the AP-inhibitory domain of mouse 
CFH linked to a CR2 targeting fragment that binds membrane-bound 
complement activation products. By comparison, CR2-FH is able to block C3 
deposition on the zymosan at least 20-fold more effectively than endogenous 
CFH [206]. CR2-FH has been shown to reduce complement activation, 
inflammation, and injury to the colon in a model of chronic dextran sulphate 
sodium-induced colitis [232], block the progression of both acute and chronic 
autoimmune demyelinating disease in an experimental encephalomyelitis study 
[233], and attenuate deficits associated with cerebral ischemia-reperfusion injury 
[234]. CR2-FH has also been used to inhibit choroidal neovascularization, a 
process requiring AP activation [81, 203] as well as smoke-induced lipid 
deposition in cultured RPE cells [126]. However, no studies have been conducted 
to test the efficacy of this AP inhibitory protein in a model of dry AMD, particularly 
using a therapeutic rather than preventative paradigm. Here, we show the first 
conclusive evidence that CR2-FH is effective in reducing or reversing smoke-
induced ocular pathology which models elements of dry AMD.
 We previously showed that preventing AP complement activation (CFB KO 
mice) prevented the development of all CE-mediated structural and functional 
alterations [202]. Here, we asked whether CR2-FH can accelerate the reversal of 
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pathology when applied weekly. Remarkably, we found that smoke-induced 
decreases in contrast sensitivity can be completely reversed following treatment 
with CR2-FH. Functional improvement was found to correlate with an attenuation 
of morphological differences in RPE-BrM. Not only did CR2-FH reverse the trend 
towards a thicker BrM and increases in OCL deposit formation caused by CE, but 
also reversed alterations in the choriocapillaris, including restoration of 
fenestrations in areas of close proximity to OCL deposits. In addition, CR2-FH 
was effective in reversing all mitochondrial impairments observed under smoke 
conditions. Our data suggests that inhibition of the AP of complement is 
paramount to reversing ocular smoke pathology, and CR2-FH appears to be a 
potent inhibitor of this pathway. However, further experiments need to be 
conducted to determine the therapeutic window, most effective dosage, and ideal 
delivery modality for this AP inhibitor following chronic cigarette smoke exposure 
or other complement-dependent AMD models. Our data supports some of the 
findings of the Phase II clinical trial for lampalizumab [235], an anti-factor D 
monoclonal antibody applied intravitreally. In this study, 129 patients with bilateral 
GA were treated monthly with either 10 mg lampalizumab or vehicle. When 
analyzed as a group at 18 months, lampalizumab-treated patients showed a 
~20% reduction in the size of GA lesions (n.s.); whereas, a subgroup analysis 
revealed that patients with a CFI mutation have a much greater response (~44%; 
P<0.005) (summarized in [236]).
 There is a growing body of evidence linking oxidative stress, cigarette 
smoking, and complement activation to the development and progression of 
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AMD. Our data provided here show that CE in mice causes behavioral and 
morphological defects in the retina, RPE, BrM, and choriocapillaris, similar to 
what is observed in patients with dry AMD. Our experiments, utilizing CR2-FH 
administered to mice following CE, provide the first evidence that complement-
based therapy is effective in treating smoke-induced ocular pathology, and 






 AMD is a multifactorial disease that causes progressive impairment of 
central vision, and is considered the leading cause of severe vision loss and 
blindness in elderly Western populations. Genetic susceptibility, environmental 
factors, and metabolic conditions all contribute to the clinical manifestation of the 
disease. AMD cases are classified as atrophic (85-90%) or exudative (10-15%). 
Treatment options for exudative AMD are well established and effective, but 
therapies designed to treat atrophic AMD are just now beginning to fully be 
explored. In order to better study the therapeutic efficacy of anti-complement-
based therapy for the treatment of dry AMD, we used a chronic cigarette smoke 
model in mice. A large body of literature exists linking this model to elements of 
AMD pathology. Endoplasmic reticulum stress markers were found to be elevated 
in the RPE of mice after 6 months of cigarette smoke exposure [224]. Chronic 
cigarette smoke exposure has been shown to result in the formation of sub-RPE 
deposits and a thickening of BrM [152], in addition to ultrastructural damage to 
the RPE and BrM and RPE cell apoptosis [66]. Nakayama and colleagues 
showed that 12 weeks of exposure to mainstream cigarette smoke can cause 
CNV in mice, providing a link to exudative AMD as well [237]. Although much of 
the pathology of AMD has already been established, the exact mechanisms 
underlying the disease remain to be elucidated.
Mechanisms of AMD
 AMD is a complex disease, likely influenced by a number of different 
factors. The primary mechanisms involved in the pathogenesis of AMD, 
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highlighting contributions from cigarette smoke, are outlined below (Fig. 4.1). 
These include oxidative damage, impaired choroidal circulation, and complement 
activation. Oxidative damage in AMD is a result of oxidative stress and 
antioxidant depletion. The RPE is under a high degree of oxidative stress at 
baseline due to the turnover of photoreceptors. Smoking increases this oxidative 
load via the introduction of smoke-derived free-radicals [64] and depletion of the 
antioxidant system [129]. Zafrilla and colleagues demonstrated that AMD patients 
display an altered metabolic state of oxidation-reduction, via decreased levels of 
SOD activity, glutathione reductase, and glutathione peroxidase [238]. Oxidative 
damage can cause problems with ocular blood flow and endothelial function that 
is amenable to antioxidant treatment. Pemp and colleagues found that 
antioxidants reduced oxidative-stress induced endothelial dysfunction, possibly 














activation of complement 




toxic smoke constituents 
(cadmium, acrolein) 
oxidative damage 
Oxidative Stress Antioxidant Depletion 
"dietary antioxidants 









 Impaired choroidal circulation may be a result of vasoconstriction and 
thrombosis. Nicotine, a primary constituent of cigarette smoke, exerts 
vasoconstriction via alpha-adrenergic receptor activation. This mechanism of 
vasoconstriction may be associated with an increased risk of developing AMD in 
smokers. The expression of nitric oxide synthase was found to be reduced in 
AMD eyes compared to controls [240]. Nitric oxide production by vascular 
endothelium is essential for the regulation of blood flow, and low levels of NOS 
may be associated with vasoconstriction and hemodynamic changes observed in 
Figure 4.1 Mechanisms of AMD pathogenesis. The primary mechanisms involved in 
the pathogenesis of AMD, particularly as they relate to cigarette smoke are depicted. 
Oxidative damage, complement activation, and impaired choroidal circulation all 
contribute to RPE degradation and drusen formation, the two hallmark features of 
atrophic AMD. The disease can then progress to the exudative form as new vessels 
infiltrate the compromised RPE/BrM.
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AMD. A positive correlation was found between plasma fibrinogen levels and 
AMD [241] and exudative AMD [242]. Fibrinogen is a glycoprotein thats helps in 
the formation of blood clots. Furthermore, cigarette smoke, a primary risk factor 
for AMD, causes changes in clot dynamics and altered fibrin architecture, 
contributing to heightened thrombogenicity [40].
 The association of inflammation with AMD pathogenesis is well 
established. Serum markers of inflammation (high-sensitivity C-reactive protein, 
tumor necrosis factor-alpha receptor 2, interluekin-6) were found to be 
associated with the incidence of early AMD [243]. Inflammation is likely due to 
enhanced activation of complement components in conjunction with a decrease 
in the amount of complement inhibitors. Numerous studies have demonstrated 
the presence of complement components in drusen and the RPE of AMD 
patients [136, 209, 244], suggesting that the complement system is more active 
in these individuals. Furthermore, gene variants for these complement proteins 
have been linked to AMD risk [245]. Johnson and colleagues suggested that CFH 
dysfunction may lead to excessive inflammation and tissue damage in AMD 
[246]. Introduction of CR2-FH, a recombinant form of CFH, was shown to reduce 
RPE injury and angiogenesis in a mouse model of AMD [81].
Treatments for AMD
 Currently, the only therapy available for dry AMD is the daily intake of 
antioxidants. Since the retina is highly susceptible to oxidative stress, 
administration of antioxidants may prevent damage stemming from ROS. 
According to the AREDS, the use of antioxidants (vitamin C, vitamin E, and beta-
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carotene) plus zinc and copper reduced the odds of developing advanced AMD 
in a randomized control trial [247]. Smailhodzic and colleagues showed that daily 
intake of zinc supplements for 3 months significantly reduced excessive systemic 
complement activation in AMD patients [248]. This finding suggests that the 
therapeutic efficacy of zinc is linked to regulation of the complement system, 
which left unchecked can lead to the accumulation of subretinal deposits. It is 
important to note that in these studies the benefit of antioxidant intake is limited 
to delaying the progression of AMD. A review conducted by Chong and 
colleagues demonstrated that vitamin A, vitamin C, vitamin E, zinc, lutein, 
zeaxanthin, alpha- and beta-carotene, beta-cryptoxanthin, and lycopene had little 
or no effect in the primary prevention of early AMD [249]. Vitamins B9, B12, and 
B6 are studied for their ability to decrease serum levels of homocysteine which, if 
elevated, can increase susceptibility to endothelial injury and inflammation. In a 
randomized trial conducted by Christen and colleagues, individuals who took 
daily supplements of vitamins B9, B12, and B6 had a decreased risk of 
developing AMD [250].
 New therapeutic strategies for dry AMD are being explored targeting 
drusen formation, inflammation, oxidative stress, accumulation of toxic by-
products, choroidal perfusion, RPE cells, and photoreceptors [251]. Several 
studies show a correlation between AMD drusen and AD plaques, since both 
contain amyloid-beta along with activated complement components [7, 252, 253]. 
Glatiramer acetate is a novel drug in testing that has been shown to reduce both 
AD plaques and drusen formation in mouse models of AMD [254, 255]. Reduced 
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drusen formation can alleviate the blockage of nutrient and waste exchange at 
the RPE/BrM/CC interface, thereby allowing the RPE to function normally. Other 
therapeutics in development for reducing inflammation aim to eliminate excessive 
activation of complement, thereby reducing subsequent immune-mediated 
damage to the RPE. Lampalizumab, an antibody against CFD, has been shown 
to reduce GA lesion progression by 20.4% at 18 months following monthly 
intravitreal injection in AMD patients [235]; this reduction was increased to 44% in 
a subpopulation that was positive for the complement factor I biomarker. 
Neuroprotective drugs such as brimonidine tartrate, an alpha-2 adrenergic 
receptor agonist, help to reduce oxidative stress by preventing apoptosis of 
viable photoreceptors. Brimonidine tartrate has been shown to stimulate the 
production of neurotrophic factors and preserve photoreceptor cells in rats 
following retinal ischemic injury [256]. These drugs, which provide 
neuroprotection for photoreceptors, are benefical in preserving visual function. 
Fenretinide and ALK-001 are two drugs in development to slow down 
photoreceptor activity, thereby reducing the accumulation of toxic by-products 
from the visual cycle such as N-retinylidene-N-retinylethanolamine (A2-E) and 
lipofuscin. Photooxidation of these by-products is postulated to trigger 
complement attack, predisposing the RPE to disease and chronic inflammation 
[257]. Fenretinide decreases the amount of vitamin A, a necessary component 
for A2-E biosynthesis, and also reduces angiogenesis and inflammation [258]. 
ALK-001 is a modified vitamin A that is unable to dimerize with other vitamin A 
molecules to form A2-E and lipofuscin [259]. Other drugs have been tested for 
108
their efficacy in enhancing choroidal circulation. Sildenafil, a potent 
phosphodiesterase 5 inhibitor, induces vasodilation of smooth muscle and has 
been shown to enhance choroidal blood flow [260]. Enhanced choroidal blood 
flow may improve RPE viability by supporting increased nutrient/waste exchange. 
Finally, a new approach has recently emerged which employs the use of 
embryonic stem cells isolated from human blastocysts. These cells are 
pluripotent in vitro and capable of differentiating into new RPE or photoreceptor 
cells based on how they are stimulated. Transplantation of rod precursors has 
been shown to improve vision in mice lacking rod function [261, 262]. A recent 
study followed dry AMD patients one year following subretinal transplantation of 
human embryonic stem cell-derived RPE, and reported a significant increase in 
visual acuity with no evidence of adverse proliferation, tumorigenicity, or ectopic 
tissue formation [263].
 Wet AMD is characterized by abnormal blood vessel growth from the 
choroid into the subretinal space, where blood and fluids cause degeneration of 
the light-sensitive photoreceptors. Therefore, the main goal in the treatment of 
exudative AMD is to inhibit CNV [264]. Initially, treatment options for wet AMD 
were limited to laser techniques. Gerhard Meyer-Schwickerath, a German 
ophthalmologist, was the first to experiment with an optical method to coagulate 
the retina using a focused beam of light [265]. Now called laser 
photocoagulation, this outpatient procedure utilizes a high-energy laser beam to 
focus on areas of CNV, which cauterizes invading blood vessels. However, scar 
formation can occur at the site of the burn, and this may cause a permanent blind 
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spot in the patient’s visual field. Additionally, most patients require retreatment 
after 2-3 years due to the invasion of new blood vessels. Only about 15% of 
patients with exudative AMD can be effectively treated with laser 
photocoagulation [266]. One reason for this is that laser photocoagulation is most 
effective when CNV is clustered close together. Blood vessels scattered over a 
wide area are much more difficult to treat using this method and typically result in 
a poor clinical outcome. 
 Photodynamic therapy (PDT) is similar to thermal laser treatment, but 
utilizes a low-power, “cool” laser in conjunction with a light-activated drug known 
as a photosensitizer. Photosensitizers, in the presence of oxygen, produce highly 
reactive, short-lived singlet oxygen and other ROS when stimulated by light, 
resulting in local damage to surrounding cells. The photosensitizer, verteporfin 
(Visudyne), is commonly used in the treatment of wet AMD, because it causes 
endothelial damage and blood vessel blockage following light activation [267]. 
The PDT procedure begins with an injection of a photosensitizer into the patient’s 
arm, where it enters systemic circulation and spreads to abnormal target vessels 
beneath the retina. Next, a low-power laser is focussed directly on areas of CNV, 
which activates the photosensitizer and, in turn, destroys the problem 
vasculature. Multiple treatments are often required with this therapy due to the 
fact that vessels may reopen. Although PDT has been shown to reduce visual 
acuity loss associated with the natural progression of exudative AMD [268], many 
patients still develop moderate or severe vision loss after treatment [269, 270].
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 Anti-angiogenic therapy is the most common treatment used for patients 
with wet AMD. In 1956, George Wise postulated that “pure retinal 
neovascularization is directly related to a tissue state of relative retinal anoxia. 
Under such circumstances, an unknown factor x develops in this tissue and 
stimulates new vessel formation, primarily from the capillaries and veins” [271]. 
This “factor x,” known today as VEGF, is a potent angiogenic factor involved in 
bone formation [272], wound healing [273], and development [274]. Blocking 
VEGF reduces the growth of abnormal blood vessels, resulting in decreased 
leakage, attenuated photoreceptor cell loss, and ultimately, a slower rate of vision 
loss. The most common anti-VEGF drugs used today are bevacizumab (Avastin), 
ranibizumab (Lucentis), and aflibercept (Eylea). Although recent studies have 
shown that bevacizumab and ranibizumab increase visual acuity in patients with 
wet AMD [275, 276]; however, bevacizumab has not been approved for 
intraocular use by the US FDA. The newest of the three, aflibercept, has the 
same efficacy as monthly intravitreal injections of ranibizumab, but only requires 
injections every 8 weeks [277]. However, off-label usage of bevacizumab is often 
preferred due to the cheaper costs associated with the drug. These drugs are 
administered via intravitreal injection into the patient’s eye. Typically, injections 
must be given on a monthly basis to maintain therapeutic efficacy. Although this 
treatment often provides great benefit for patients, the frequency is often 
associated with a significant financial and physical burden.
 In addition to the classic anti-VEGF therapies, other mediators of VEGF 
expression are being targeted in the treatment of exudative AMD. Transforming 
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growth factor-beta (TGF-β) is one such mediator that participates in cell 
proliferation and differentiation during angiogenesis. Studies show that TGF-β 
significantly enhances VEGF secretion and vascular permeability along with 
other cytokines such as necrosis factor alpha [278, 279]. Thus, TGF-β inhibition 
may be a useful adjunctive therapeutic strategy for use with anti-VEGF therapy. 
Semaphorin 3A is a potent chemorepellent guidance molecule involved in axonal 
growth cone guidance and vessel network formation [280, 281]. Bai and 
colleagues showed that semaphorin 3A inhibited laser-induced CNV formation in 
mice and inhibited the uptake of VEGF and TGF-β [282]. Alternative targets for 
the treatment of wet AMD are macrophages which play a critical role in the 
development of CNV. Tumor necrosis factor-inducible gene 6 protein (TSG-6) is 
an endogenous protein involved in extracellular matrix stability, cell migration, 
and regulating macrophage activation. Kim and colleagues demonstrated that 
TSG-6 suppressed the expression of VEGF and pro-inflammatory cytokines, 
inhibited recruitment of CCR2(+) monocytes, and reduced the size of CNV 
lesions in mice following laser-induced CNV formation.
Conclusions
 We can draw several conclusions based on the results of this study. First, 
we have demonstrated that the cigarette smoke model is a useful tool for 
studying AMD pathology. A number of parallels exist between the clinical 
presentation of AMD patients and observations noted from mice exposed to 
chronic cigarette smoke for 6 months. Poor contrast sensitivity was the first 
parallel observed in mice following CE, measured using the OKR test. A recent 
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study reported that AMD patients had significantly lower scores in the Spaeth/
Richman Contrast Sensitivity test versus controls [283]. The second parallel 
observed in smoke-exposed animals was the presence of extracellular deposits 
in BrM, visualized using electron microscopy. These deposits are reminiscent of 
drusen, the hallmark sign of dry AMD. In fact, the only notable difference 
between the two is the location in which they are found. Drusen are found 
between the basement membrane of the RPE and the ICL of BrM, while the 
deposits we observed were present in the area between the OCL of BrM and the 
basement membrane of the CC. The presence of these OCL deposits in mice 
exposed to CE was accompanied by an overall thickening of BrM. This finding 
corresponds to human studies that report a thickening of BrM in patients with dry 
AMD [284], marking a third parallel between the cigarette smoke model and 
AMD. The fourth and final parallel observed was a thinning of the ONL, 
determined via OCT and histological analysis. The primary clinical characteristic 
of advanced stage, dry AMD is GA. These areas of hypopigmentation, 
representing areas of RPE degeneration, lead to islands of lost photoreceptors. 
Photoreceptor atrophy has been quantified in patients with AMD via a thinning of 
the ONL [10]. The cause of ONL thinning observed in smoke-exposed mice likely 
differs from that observed in AMD patients with GA. If ONL thinning was a result 
of lost photoreceptors, we would expect to see differences in spatial frequency 
and photoreceptor cell count, which we did not. Instead, we noticed a decrease 
in contrast sensitivity along with a reduction in expression of cone opsins and 
RPE65, suggesting a decrease in photoreceptor sensitivity. This decrease in 
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sensitivity may be due to Müller cell atrophy, which is the likely cause of the ONL 
thinning observed in our experiments. Our findings validate the cigarette smoke 
model and its application in studying AMD, particularly the atrophic form of the 
disease.
 Second, we have demonstrated that the AP of complement plays an 
integral role in the development of cigarette smoke-induced ocular pathology. 
Using a CFB knockout mouse, we were able to selectively inhibit the AP of 
complement, while maintaining the classical and lectin pathways. We found that 
these animals were unaffected by cigarette smoke in almost every metric. By 
comparison, WT mice exposed to long-term cigarette smoke inhalation exhibited 
functional (ERG) and behavioral (OKR) deficits in retinal function, alterations in 
gene regulation pathways (photoreceptor signal transduction, RPE cell 
metabolism, complement activation, angiogenesis), morphological changes in 
RPE-BrM (thickening of BrM, deposit formation in the OCL of BrM, dislocated 
mitochondria), and retinal thinning (ONL, INL). The robust differences observed 
between WT and CFB knockout animals following long-term smoke exposure 
suggest that the AP is necessary for induction of smoke-induced ocular damage. 
Several CFB polymorphisms have been characterized as protective against 
AMD. The rs641153 allele of CFB is protective against large drusen and drusen 
covered area [285], which are positively correlated with risk for developing AMD. 
A meta-analysis conducted by Thakkinstian and colleagues reported that the 
rs4151667 and rs641153 alleles of CFB carried estimated risks of 0.54 and 0.41 
(odds ratios), respectively, conferring a reduced risk of developing AMD [286]. 
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Another study showed that deletions of CFH-related genes CFHR3 and CFHR1 
is protective against AMD. CFHR3 and CFHR1 compete with CFH for binding to 
C3. Therefore, a deficiency of CFHR3 and CFHR1 is thought to enhance local 
regulation of the AP by CFH [287]. Taken together, these findings suggest that 
the AP of complement plays a pivotal role in the development of cigarette smoke-
induced ocular pathology and AMD.
 Finally, we have shown that smoke-induced ocular pathology is amenable 
to anti-complement-based therapy. Mice were exposed to cigarette smoke for 6 
months, then treated under room air conditions for 3 months with a modified 
version of CFH, an AP inhibitor, to determine if smoke-induced ocular pathology 
is reversible. Specifically, we wanted to know whether smoke pathology can be 
reduced after cessation. We found that smoke-exposed mice treated with CR2-
FH exhibited normal visual acuity, retinal morphology, and retinal thickness 
compared to vehicle controls. These findings provide additional support for our 
hypothesis that the AP of complement is necessary for the development of long-
term smoke-induced ocular pathology. Additionally, these findings suggest that 
CR2-FH can effectively reverse retinal deficits associated with cigarette smoke 
pathology, and provide a platform to test the efficacy of CR2-FH for the treatment 
of AMD. The Y402H risk variant of CFH, which is associated with an increased 
risk of developing AMD, was correlated with AP complement activation [288]. 
However, the beneficial effects of CFH extends beyond its inhibitory action on the 
AP. Weismann and colleagues showed that CFH binds to MDA, a common lipid 
peroxidation product found in AMD, and blocks the uptake of MDA-modified 
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proteins by macrophages in mice [125]. Taken together, these findings suggest 
that anti-complement-based therapies, such as CR2-FH, may provide a powerful 
new therapeutic approach for treating AMD. The present study provides a 
foundation for the exploration of novel anti-complement-based therapies for use 
in the treatment of AMD, but further research needs to be conducted to fully 
elucidate the mechanisms underlying the disease. Future studies using aged 
mice may provide a more accurate model of dry AMD. Also, the influence of 
gender on cigarette smoke pathology remains to be elucidated (i.e. the 
interaction of CE and menopausal changes in estrogen levels). Finally, the role of 
the classical and lectin pathways of complement in smoke-induced ocular 
pathology still requires investigation.
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Appendix
Detection of CFB and RD8 Mutations by PCR
 PCR-ready DNA was prepared from mouse tail biopsy samples using 
HotSHOT alkaline lysis and neutralizing reagents [289]. PCR amplification for 
each reaction was carried out using 15 µl of GoTaq green master mix (Promega, 
M7122), 10 µl of nuclease-free water, and 1 µl of each diluted primer per 5 µl of 
DNA template. PCR primers for complement factor B (CFB) deficiency detection 
were as follows: 5’-CCGAAGCATTCCTATCCTCC-3’, 5’-
CAGATGGGCTGACCGCTTCC-3’, and 5’-
CTAGTCTTGTCTGCTTTCTCC-3’ [290]. Reactions for CFB were initially 
denatured at 95˚C for 5 minutes followed by 38 cycles at 95˚C for 60 seconds, 
54˚C for 60 seconds, 72˚C for 60 seconds, and a final extension at 72˚C for 10 
minutes. Amplified DNA samples for CFB mutation detection were run with an 
aliquot of GeneRuler 100 bp Plus DNA ladder (Fermentas, SM0323). Amplicon 
sizes for the CFB wild type and mutant allele is equal to 748 and 610 bp, 
respectively. Primer sequences for the detection of an RD8 mutation included 
mCrb 1, mF1: 5’-GTGAAGACAGCTACAGTTCTGATC-3’; mCrb 1, mF2: 5’-
GCCCCTGTTTGCATGGAGGAAACTTGGAAGACAGCTACAGTTCTTCTG-3’; 
and mCrb 1, mR: 5’-GCCCCATTTGCACACTGATGAC-3’ [291]. In order to get 
the best PCR amplification results of RD8 sequences, the mF1 and mR primer 
amounts were doubled to compensate for the larger mF2 primer. PCR reactions 
for RD8 were denatured at 94˚C for 5 minutes followed by 35 cycles at 94˚C for 
30 seconds, 65˚C for 30 seconds, 72˚C for 30 seconds, and a final extension at 
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72˚C for 10 minutes. Amplified DNA samples for RD8 mutation detection were 
run against the 50 bp HyperLadderV (Bioline, BIO-33057). Amplicon sizes for the 
RD8 wild type and mutant allele is equal to 220 and 244 bp, respectively. Since 
the RD8 wild type and mutant amplification products have a similar molecular 
weight, primer set reactions were carried out separately for each DNA template. 
Amplified DNA samples and corresponding ladders were separated using a 1.5% 
agarose gel containing ethidium bromide and visualized under UV light.  
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